<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">61973</article-id><article-id pub-id-type="doi">10.7554/eLife.61973</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Improving oligo-conjugated antibody signal in multimodal single-cell analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-201754"><name><surname>Buus</surname><given-names>Terkild B</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7180-6384</contrib-id><email>terkild.buus@sund.ku.dk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-201755"><name><surname>Herrera</surname><given-names>Alberto</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4189-9051</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-201756"><name><surname>Ivanova</surname><given-names>Ellie</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1850-9505</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-201757"><name><surname>Mimitou</surname><given-names>Eleni</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9737-6394</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-201758"><name><surname>Cheng</surname><given-names>Anthony</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0778-8238</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-166824"><name><surname>Herati</surname><given-names>Ramin S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2613-4050</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-201759"><name><surname>Papagiannakopoulos</surname><given-names>Thales</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2251-1624</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-171208"><name><surname>Smibert</surname><given-names>Peter</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0772-1647</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-201760"><name><surname>Odum</surname><given-names>Niels</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-3135-5624</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-144235"><name><surname>Koralov</surname><given-names>Sergei B</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4843-3791</contrib-id><email>sergei.koralov@nyulangone.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Pathology, New York University School of Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>LEO Foundation Skin Immunology Research Center, University of Copenhagen</institution><addr-line><named-content content-type="city">Copenhagen</named-content></addr-line><country>Denmark</country></aff><aff id="aff3"><label>3</label><institution>Department of Immunology and Microbiology, University of Copenhagen</institution><addr-line><named-content content-type="city">Copenhagen</named-content></addr-line><country>Denmark</country></aff><aff id="aff4"><label>4</label><institution>Technology Innovation Lab, New York Genome Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Department of Genetics and Genome Sciences, University of Connecticut School of Medicine</institution><addr-line><named-content content-type="city">Farmington</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts</institution><addr-line><named-content content-type="city">Amherst</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>NYU Langone Vaccine Center, Department of Medicine, New York University School of Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Weigel</surname><given-names>Detlef</given-names></name><role>Senior Editor</role><aff><institution>Max Planck Institute for Developmental Biology</institution><country>Germany</country></aff></contrib><contrib contrib-type="editor"><name><surname>Weigel</surname><given-names>Detlef</given-names></name><role>Reviewing Editor</role><aff><institution>Max Planck Institute for Developmental Biology</institution><country>Germany</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>16</day><month>04</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e61973</elocation-id><history><date date-type="received" iso-8601-date="2020-08-10"><day>10</day><month>08</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-03-31"><day>31</day><month>03</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Buus et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Buus et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-61973-v1.pdf"/><abstract><p>Simultaneous measurement of surface proteins and gene expression within single cells using oligo-conjugated antibodies offers high-resolution snapshots of complex cell populations. Signal from oligo-conjugated antibodies is quantified by high-throughput sequencing and is highly scalable and sensitive. We investigated the response of oligo-conjugated antibodies towards four variables: concentration, staining volume, cell number at staining, and tissue. We find that staining with recommended antibody concentrations causes unnecessarily high background and amount of antibody used can be drastically reduced without loss of biological information. Reducing staining volume only affects antibodies targeting abundant epitopes used at low concentrations and is counteracted by reducing cell numbers. Adjusting concentrations increases signal, lowers background, and reduces costs. Background signal can account for a major fraction of total sequencing and is primarily derived from antibodies used at high concentrations. This study provides new insight into titration response and background of oligo-conjugated antibodies and offers concrete guidelines to improve such panels.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>CITE-seq</kwd><kwd>ECCITE-seq</kwd><kwd>scRNA-seq</kwd><kwd>cytometry</kwd><kwd>oligo-conjugated antibodies</kwd><kwd>Background signal</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL-125816</award-id><principal-award-recipient><name><surname>Koralov</surname><given-names>Sergei B</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100008271</institution-id><institution>LEO Pharma Research Foundation</institution></institution-wrap></funding-source><award-id>LF-OC-20-000351</award-id><principal-award-recipient><name><surname>Odum</surname><given-names>Niels</given-names></name><name><surname>Koralov</surname><given-names>Sergei B</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005481</institution-id><institution>NYU School of Medicine</institution></institution-wrap></funding-source><award-id>P30CA016087</award-id><principal-award-recipient><name><surname>Koralov</surname><given-names>Sergei B</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>Judith and Stewart Colton Center for Autoimmunity Pilot Grant</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Koralov</surname><given-names>Sergei B</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Drs. Martin and Dorothy Spatz Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Koralov</surname><given-names>Sergei B</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008363</institution-id><institution>Kræftens Bekæmpelse</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Buus</surname><given-names>Terkild Brink</given-names></name><name><surname>Odum</surname><given-names>Niels</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Oligo-conjugated antibodies are a powerful tool but require thorough optimization to reduce background signal, increase sensitivity, and reduce sequencing costs.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Analysis of surface proteins in multimodal single-cell genomics such as cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) is a powerful addition to conventional single-cell RNA sequencing (scRNA-seq) (<xref ref-type="bibr" rid="bib21">Stoeckius et al., 2017</xref>; <xref ref-type="bibr" rid="bib19">Peterson et al., 2017</xref>; <xref ref-type="bibr" rid="bib11">Mair et al., 2020</xref>). Unlike flow- and mass cytometry, CITE-seq is not limited by spectral overlap or availability of distinguishable isotopes (<xref ref-type="bibr" rid="bib5">Gullaksen et al., 2019</xref>; <xref ref-type="bibr" rid="bib7">Hulspas et al., 2009</xref>). This is due to the practically unlimited number of distinct oligo barcodes and discrete sequence counting, allowing high numbers of antibodies to be included in individual experiments.</p><p>While signal acquisition in CITE-seq is different, the reagents and staining procedure are highly analogous to staining for flow cytometry. Traditional titration for flow or mass cytometry aims to identify the conjugated antibody concentration, allowing the best discrimination between the signal from positive and negative cells (<xref ref-type="bibr" rid="bib5">Gullaksen et al., 2019</xref>; <xref ref-type="bibr" rid="bib8">Hulspas, 2010</xref>). Multiple factors may affect antibody binding and subsequent signal including antibody concentration, total amount of antibody, as well as the level of target expression (epitope amount). Epitope amount is governed by the number of cells and the per-cell expression of the target epitope. These factors are in turn influenced by the cellular composition of the sample as well as their activation and differentiation state. Nonspecific binding is expected to increase as the total amount of antibody molecules greatly exceeds the epitopes present in a sample. As such, nonspecific binding is dependent on the total number of antibody molecules, rather than the antibody concentration (<xref ref-type="bibr" rid="bib7">Hulspas et al., 2009</xref>). This makes staining volume, cell composition, and cell number important parameters for optimal staining (<xref ref-type="bibr" rid="bib8">Hulspas, 2010</xref>). Consequently, flow and mass cytometric optimization aims to use antibody concentrations that reach the highest signal-to-noise ratio (often reached at the ‘saturation plateau’) in a minimal volume (and thus minimal number of antibody molecules) (<xref ref-type="bibr" rid="bib5">Gullaksen et al., 2019</xref>; <xref ref-type="bibr" rid="bib24">van Vreden, 2019</xref>).</p><p>Oligo-conjugated antibody signal has been shown to be highly analogous to fluorochrome-conjugated antibodies of the same clone in flow cytometry in regards to the concentration needed to reach the ‘saturation plateau’ (<xref ref-type="bibr" rid="bib22">Stoeckius et al., 2018</xref>). However, unlike flow cytometry, where antibody (fluorescence) signal intensity has no influence on analysis cost, oligo-conjugated antibody signal is analyzed by counting sequencing reads, making costs strictly dependent on signal intensity (by requiring increased sequencing depth). This is particularly important for methods sequencing vast numbers of cells stained with a high number of antibodies such as single-cell combinatorial indexed cytometry by sequencing (SCITO-seq), where shallow sequencing is paramount for the economic feasibility of such methods (<xref ref-type="bibr" rid="bib9">Hwang, 2020</xref>). Thus, while an optimal antibody concentration in flow cytometry aims to get the highest signal-to-noise ratio, oligo-conjugated antibody staining conditions should be titrated to get sufficient signal-to-noise at the lowest possible signal intensity. In practice, this means that concentrations of most antibodies in an optimized CITE-seq panel are not intended to reach their ‘saturation plateau’, but should be within their linear concentration range (where doubling the antibody concentration leads to twice the signal). Such concentrations are much more sensitive to the number of available epitopes (i.e., cell number and cell composition) than an optimized flow cytometry panel. Unlike flow and mass cytometry, where the major source of background is autofluorescence, spillover between neighboring channels, and nonspecific binding of the antibodies (<xref ref-type="bibr" rid="bib7">Hulspas et al., 2009</xref>; <xref ref-type="bibr" rid="bib2">Au-Yeung et al., 2019</xref>), a major source of background signal for oligo-conjugated antibodies appears to be free-floating antibodies in the cell suspension (<xref ref-type="bibr" rid="bib16">Mulè et al., 2020</xref>). In droplet-based single-cell sequencing methods, these free-floating antibodies will be distributed between cell-containing and empty droplets. As signal from empty droplets can only be distinguished from signal from cell-containing droplets after sequencing and due to the much higher number of empty than cell-containing droplets, background signal can make up a considerable fraction of the sequenced reads, and thus sequencing costs.</p><p>In this study, we present a limited but practically applicable titration of four variables in a 5′-CITE-seq panel of 52 antibodies: (1) antibody concentration (fourfold dilution response), (2) staining volume (50 µL vs. 25 µL), (3) cell count (1 × 10<sup>6</sup> vs. 0.2 × 10<sup>6</sup>), and (4) tissue of origin: peripheral blood mononuclear cells (PBMCs) from healthy donor vs. immune cell compartment from a lung tumor sample. We find that oligo-conjugated antibodies show high background and limited response to titration when used above 2.5 µg/mL and that most antibodies appear to reach their saturation plateau at concentrations between 0.62 and 2.5 µg/mL. Many antibodies can be further diluted, despite being at their linear concentration range, without affecting the identification of epitope-positive cells. Reducing staining volume has a minor effect on signal and only impacts signal from antibodies used at low concentrations targeting highly expressed epitopes; this effect is counteracted by reducing the number of cells present during staining. We compare samples stained with pre-titration and adjusted concentrations of the same antibody panel and find that adjusting concentrations increases signal, lowers background, and reduces both sequencing and antibody costs. Finally, we find that background signal in empty droplets can constitute a major fraction of the total sequencing reads and is skewed towards antibodies used at high concentrations targeting epitopes present in low amounts.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Fourfold antibody dilution in PBMC and lung tumor immune cells</title><p>A panel of 52 oligo-conjugated antibodies was allocated into several groups of starting concentrations based on previous experience with each antibody, epitope abundance or following vendor recommendations (concentration range between 0.05 and 10 µg/mL; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). We stained two samples of either 10<sup>6</sup> PBMCs or 5 × 10<sup>5</sup> lung tumor leukocytes in 50 µL of antibody mixture with various starting concentrations, hereafter referred to as ‘dilution factor (DF) 1’. To determine how the signal from each antibody changed by dilution across the two tissues, we stained the same number of cells in the same volume with a four times diluted antibody mixture (DF4).</p><p>Single-cell gene expression was assessed by shallow sequencing (~4000 reads per cell) to assign cells into major cell lineages (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) and cell types (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) based on their transcriptional profile (see <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> for gene detection and unique molecular identifier (UMI) distributions and details on cell-type annotation). Leukocytes from lung tumor samples exhibited distinct transcriptional profiles within each cell type, but showed overall good co-clustering with similar cell types (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). To allow direct comparison of UMI counts from the different conditions, we reduced the number of cells included in analysis from each condition to contain the same number of cells from each cell type. By only using the gene expression modality for cell-type assignment, we can directly compare antibody-derived tag (ADT) UMI counts at different staining conditions within transcriptional subclusters without risk of having differences in ADT signal interfere with cell-type assignment.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Fourfold antibody dilution response in peripheral blood mononuclear cell (PBMC) and lung tumor immune cells.</title><p>(<bold>A–C</bold>) Single cells from all samples and conditions were clustered and visualized according to their gene expression and colored by (<bold>A</bold>) overall cell lineage, (<bold>B</bold>) cell type, and (<bold>C</bold>) tissue of origin. (<bold>D</bold>) Summarized unique molecular identifier (UMI) counts within cell-containing droplets segmented by the individual antibodies stained at the starting concentrations (dilution factor 1 [DF1]) or at a fourfold dilution (DF4) in PBMC and lung samples (concentrations of each antibody can be found in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Antibody segments are colored by their concentration at DF1. (<bold>E</bold>) Heatmap of normalized antibody-derived tag (ADT) signal within each transcription-based cluster identified in (<bold>B</bold>). Visualized by frequency of positive cells (circle size) and colored by the median ADT signal within the positive fraction (i.e., signal from a marker that is highly expressed by all cells in a cluster will have the biggest circle and be colored yellow). Red and blue colored boxes denote the clusters chosen for evaluating titration response within blood and lung samples, respectively. (<bold>F, G</bold>) Change in ADT signal for each antibody by fourfold dilution. Individual antibodies are colored by their concentration at DF1 and quantified by (<bold>F</bold>) sum of UMIs within cell-containing droplets assigned to each antibody and (<bold>G</bold>) 90th percentile UMI count within expressing cell cluster identified in (<bold>E</bold>) and annotated by numbers to the right.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Quality control metrics and cell-type annotation.</title><p>(<bold>A</bold>) Number of genes detected (top) and unique molecular identifier (UMI) count (bottom) for each cell across major cell lineages within the mRNA modality. (<bold>B</bold>) UMI count within antibody-derived tag modality across different experimental conditions and cell lineages. (<bold>C</bold>) Detailed cell-type annotation visualized by t-distributed stochastic neighbor embedding (tSNE). (<bold>D</bold>) Top five marker genes for each cell type (expressed by &gt;30% of cells and having being at least 20% more abundant compared to other cell types). Only showing dots for genes expressed in &gt;10% of the cluster.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Gating positive cells based on antibody-derived tag (ADT) signal at dilution factor 1.</title><p>Histograms for normalized ADT expression of each marker within major cell types in peripheral blood mononuclear cells (red) and lung (blue). Gating threshold indicated by vertical line, and numbers denote percent positive within each cell type of each tissue.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig1-figsupp2-v1.tif"/></fig></fig-group><p>Comparing the total ADT UMI counts from each condition, we saw fewer UMIs from samples stained with DF4 as compared with DF1, both at 77% sequencing saturation (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). However, the reduction in UMI counts from DF1 to DF4 by 38% (761,350 to 474,404) and 51% (1,121,940 to 548,393) in PBMC and lung, respectively, was markedly less than the fourfold difference (75% reduction) in antibody concentrations used in staining. It is worth noting that 4/52 antibodies used at the highest concentration (10 µg/mL) accounted for more than 20% of the total UMI counts irrespective of tissues and dilution factors and without showing any clearly positive populations (<xref ref-type="fig" rid="fig1">Figure 1D, E</xref>; gating thresholds shown in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). Indeed, we found that the majority of antibodies used in concentrations at or above 2.5 µg/mL showed minimal response to fourfold titration, both in terms of total UMI counts (<xref ref-type="fig" rid="fig1">Figure 1F</xref>) as well as UMI counts at the 90th quantile of the cell type with the highest overall expression level (<xref ref-type="fig" rid="fig1">Figure 1G</xref>; expressing cell types identified in <xref ref-type="fig" rid="fig1">Figure 1E</xref>), reflecting the response within the positive population where such could be identified. In contrast, antibodies used in concentrations at or below 0.62 µg/mL all showed close to linear response to fourfold dilution (shown as a reduction around two ‘logs’ on a log2 scale; <xref ref-type="fig" rid="fig1">Figure 1F, G</xref>). This indicates that the signal for many antibodies reach their saturation plateau in the range between 0.62 and 2.5 µg/mL, and that higher concentrations are likely to only increase the background signal.</p><p>In the present antibody panel, the response to fourfold dilution can be divided into five categories (<xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplements 1</xref>–<xref ref-type="fig" rid="fig2s5">5</xref>) that warrant different considerations in the choice of whether to reduce concentration or not. For category A (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), reducing concentration is always the right choice. For the other categories (<xref ref-type="fig" rid="fig2">Figure 2B–E</xref>), the choice of whether to reduce concentration or not depends on the balance between the need for signal and the economic cost of signal (see <xref ref-type="table" rid="table1">Table 1</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Fourfold antibody dilution response is dependent on epitope abundance.</title><p>Titration plots (unique molecular identifier [UMI] count vs. cell rank) showing response to reduction in antibody concentration from dilution factor 1 (DF1) to DF4 within peripheral blood mononuclear cells (left) and lung (right). Histogram depicts distribution of UMIs at each condition colored by dilution factor (and annotated with concentration). Numbers within bar plot denote total UMI count within cell-containing droplets at each antibody concentration. Barcodes to the right depict cell type by color at the corresponding rank to visualize specificity of the antibody. Horizontal line depicts gating threshold for cells considered positive for the marker. Antibody response to fourfold dilution can be divided into five categories exemplified in (<bold>A-E</bold>). (<bold>A</bold>) Antibodies where the positive signal is obscured within the background signal (category A). (<bold>B</bold>) Antibodies that respond by a reduction in signal but without hampering the ability to distinguish positive from negative cells (category B). These antibodies also show strict cell-type specificity (i.e., HLA-DR is restricted to non-T cells, whereas CD4 is highly expressed in T cells and intermediately expressed in myeloid cells as shown in the barcode plot). (<bold>C</bold>) Antibodies that respond by a reduction in both signal and change the ability to distinguish positive from negative cells (category C). (<bold>D</bold>) Antibodies targeting ubiquitously expressed markers (category D). (<bold>E</bold>) Antibodies that do not show a convincing positive population due to either lack of epitopes (no positive cells in either tissue) or lack of antibody binding (non-functional antibody) (category E). Titration plots for all markers can be found in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplements 1</xref>–<xref ref-type="fig" rid="fig2s5">5</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Response of individual antibodies to fourfold reduction in concentration in peripheral blood mononuclear cells (PBMCs) and lung tumor immune cells – category A.</title><p>Titration plots (unique molecular identifier [UMI] count vs. cell rank) showing response to reduction in antibody concentration from dilution factor 1 (DF1) to DF4 within PBMC (left) and lung (right) within antibodies assigned to category A. Histogram depicts distribution of UMIs at each condition colored by dilution factor (and annotated with concentration). Numbers within bar plot denote total UMI count within cell-containing droplets at each antibody concentration. Barcodes to the right depict cell type by color at the corresponding rank to visualize specificity of the antibody. Horizontal line depicts gating threshold for cells considered positive for the marker.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Response of individual antibodies to fourfold reduction in concentration in peripheral blood mononuclear cells (PBMCs) and lung tumor immune cells – category B.</title><p>Titration plots (unique molecular identifier [UMI] count vs. cell rank) showing response to reduction in antibody concentration from dilution factor 1 (DF1) to DF4 within PBMC (left) and lung (right) within antibodies assigned to category B. Histogram depicts distribution of UMIs at each condition colored by dilution factor (and annotated with concentration). Numbers within bar plot denote total UMI count within cell-containing droplets at each antibody concentration. Barcodes to the right depict cell type by color at the corresponding rank to visualize specificity of the antibody. Horizontal line depicts gating threshold for cells considered positive for the marker.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Response of individual antibodies to fourfold reduction in concentration in peripheral blood mononuclear cells (PBMCs) and lung tumor immune cells – category C.</title><p>Titration plots (unique molecular identifier [UMI] count vs. cell rank) showing response to reduction in antibody concentration from dilution factor 1 (DF1) to DF4 within PBMC (left) and lung (right) within antibodies assigned to category C. Histogram depicts distribution of UMIs at each condition colored by dilution factor (and annotated with concentration). Numbers within bar plot denote total UMI count within cell-containing droplets at each antibody concentration. Barcodes to the right depict cell type by color at the corresponding rank to visualize specificity of the antibody. Horizontal line depicts gating threshold for cells considered positive for the marker.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig2-figsupp3-v1.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Response of individual antibodies to fourfold reduction in concentration in peripheral blood mononuclear cells (PBMCs) and lung tumor immune cells – category D.</title><p>Titration plots (unique molecular identifier [UMI] count vs. cell rank) showing response to reduction in antibody concentration from dilution factor 1 (DF1) to DF4 within PBMC (left) and lung (right) within antibodies assigned to category D. Histogram depicts distribution of UMIs at each condition colored by dilution factor (and annotated with concentration). Numbers within bar plot denote total UMI count within cell-containing droplets at each antibody concentration. Barcodes to the right depict cell type by color at the corresponding rank to visualize specificity of the antibody. Horizontal line depicts gating threshold for cells considered positive for the marker.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig2-figsupp4-v1.tif"/></fig><fig id="fig2s5" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 5.</label><caption><title>Response of individual antibodies to fourfold reduction in concentration in peripheral blood mononuclear cells (PBMCs) and lung tumor immune cells – category E.</title><p>Titration plots (unique molecular identifier [UMI] count vs. cell rank) showing response to reduction in antibody concentration from dilution factor 1 (DF1) to DF4 within PBMC (left) and lung (right) within antibodies assigned to category E. Histogram depicts distribution of UMIs at each condition colored by dilution factor (and annotated with concentration). Numbers within bar plot denote total UMI count within cell-containing droplets at each antibody concentration. Barcodes to the right depict cell type by color at the corresponding rank to visualize specificity of the antibody. Horizontal line depicts gating threshold for cells considered positive for the marker.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig2-figsupp5-v1.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Five categories of response to fourfold dilution.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Categories</th><th valign="top">Responses to fourfold dilution</th><th valign="top">Markers</th><th valign="top">Considerations</th></tr></thead><tbody><tr><td valign="top">A <break/>(<xref ref-type="fig" rid="fig2">Figure 2A</xref>)</td><td valign="top">Antibodies exhibiting no response to dilution, indicating that the positive signal is fully saturated, absent, or obscured within high background signal.</td><td valign="top"><italic>CD1a, CD30, CD86, CD134, CD138, CD152, CD183, CD197, CD279, CD336, IgG1, IgG2A,</italic> and <italic>TCRgd</italic></td><td valign="top">Reducing antibody concentration is always the right choice. These antibodies sequester a large amount of unique molecular identifiers without yielding critical insight. Reducing concentration may reveal a true positive population obscured by the background signal.</td></tr><tr><td valign="top">B <break/>(<xref ref-type="fig" rid="fig2">Figure 2B</xref>)</td><td valign="top">Antibodies that respond by a reduction in signal but without hampering the ability to distinguish positive and negative fractions.</td><td valign="top"><italic>CD4, CD5, CD8, CD11b, CD19, CD62L, CD69, CD103, CD107a, CD194, CD274, EpCAM, HLA-DR,</italic> and <italic>TCRab</italic></td><td valign="top">Reducing antibody concentrations will be economically beneficial with minimal loss of biological information. For instance, In the lung at dilution factor 1, HLA-DR uses 9% of the total unique molecular identifier counts within cell-containing droplets and can be reduced at least fourfold without any apparent change in ability to discriminate between positive and negative cells.</td></tr><tr><td valign="top">C <break/>(<xref ref-type="fig" rid="fig2">Figure 2C</xref>)</td><td valign="top">Antibodies that respond by a reduction in signal that subsequently changes the ability to distinguish positive from negative cells or bring the cutoff value for positive cells down to only a few unique molecular identifiers.</td><td valign="top"><italic>CD1c, CD2, CD3, CD14, CD25, CD26, CD28, CD31, CD39, CD45RA, CD45RO,</italic> and <italic>CD141</italic></td><td valign="top">Reducing antibody concentration will reduce biological information as cells expressing the targeted epitopes may not exhibit sufficient signal. If only cells expressing high levels of the marker need to exhibit signal, these can be slightly reduced.</td></tr><tr><td valign="top">D <break/>(<xref ref-type="fig" rid="fig2">Figure 2D</xref>)</td><td valign="top">Antibodies that respond linearly to titration but take up high numbers of unique molecular identifiers due to targeting (almost) ubiquitously expressed markers.</td><td valign="top"><italic>CD44, CD45,</italic> and <italic>HLA-ABC</italic></td><td valign="top">These can be reduced if all cells exhibit high unique molecular identifier counts. Unless these markers have a clear purpose, most experiments will benefit from dropping them from the panel as they tend to sequester a large proportion of total sequencing reads with little biological information.</td></tr><tr><td valign="top">E <break/>(<xref ref-type="fig" rid="fig2">Figure 2E</xref>)</td><td valign="top">Antibodies where response is hard to assess due to not showing expected positive population either due to lack of epitopes (no positive cells in either tissue) or lack of antibody binding (non-functional antibody).</td><td valign="top"><italic>CD24, CD56, CD66b, CD70, CD80, CD117, CD123, CD127, CD196,</italic> and <italic>CD223</italic></td><td valign="top">Should be evaluated individually. Is there prior information indicating that this marker is expressed by cells in these types of samples? Do any cells in the sample express high levels of the gene encoding the targeted protein? If so, increasing the concentration of the antibody or trying a different clone may yield better signal.</td></tr></tbody></table></table-wrap></sec><sec id="s2-2"><title>Reducing staining volume primarily affects highly expressed markers</title><p>To investigate the effect on ADT signal caused by further reducing the staining volume, we included PBMC samples stained with the same concentration of antibodies in 50 µL or 25 µL (effectively using half the amount of antibodies at twice the cell density). In both samples, we used the DF4 panel on 10<sup>6</sup> cells to assess the worst-case scenario of the reduction as the amount of epitopes in this setting is likely to be competing for antibodies that are not in excess. Despite having many antibodies responding linearly to concentration reduction (<xref ref-type="fig" rid="fig1">Figure 1</xref>), we found much less response to reduced staining volume, both in regard to total number of UMIs (9% reduced; 469,541 to 428,680) and on a marker by marker basis (<xref ref-type="fig" rid="fig3">Figure 3A–C</xref>). As expected, antibodies used in low concentrations (0.0125–0.025 µg/mL) targeting highly abundant epitopes were most severely affected by the reduced staining volume (such as CD31, CD44, and CD45; <xref ref-type="fig" rid="fig3">Figure 3D, E</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref> and <xref ref-type="fig" rid="fig3s2">2</xref>), whereas antibodies targeting less abundant epitopes were largely unaffected (such as CD8 and CD19; <xref ref-type="fig" rid="fig3">Figure 3F</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Reducing staining volume primarily affects highly expressed markers.</title><p>Comparison of peripheral blood mononuclear cell samples stained in 50 µL (same sample as dilution factor [DF] 4 in <xref ref-type="fig" rid="fig1">Figure 1</xref>) or 25 µL volume at DF4. (<bold>A</bold>) Summarized unique molecular identifier (UMI) counts within cell-containing droplets segmented by the individual antibodies colored by their concentration. (<bold>B, C</bold>) Change in antibody-derived tag signal for each antibody by reducing staining volume from 50 to 25 µL. Individual antibodies are colored by their concentration. Quantified by (<bold>B</bold>) sum of UMIs within cell-containing droplets assigned to each antibody and (<bold>C</bold>) 90th percentile UMI count within the cell type with most abundant expression (the assayed cell type is annotated to the right). (<bold>D</bold>) Titration plot (marker UMI count vs. normalized cell rank) for CD31 signal response when reducing staining volume from 50 µL to 25 µL. Histogram depicts distribution of UMIs at each condition. Barcodes to the right depict cell-type occurrence at the corresponding rank to visualize cell specificity of the antibody. Numbers on top of the small bar plot denote total UMI count assigned to CD31 within cell-containing droplets from each condition. (<bold>E</bold>, <bold>F</bold>) Non-normalized UMI counts visualized on t-distributed stochastic neighbor embedding (tSNE) plots of an affected (CD31; <bold>E</bold>) or an unaffected (CD8; <bold>F</bold>) marker by the reduction in cell density. Dashed line indicates the region where expression levels vary between volumes. Titration plots for all markers can be found in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref> and <xref ref-type="fig" rid="fig3s2">2</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Response of individual antibodies to reduction in staining volume.</title><p>Titration plots (unique molecular identifier [UMI] count vs. cell rank) showing response to reducing staining volume from 50 µL to 25 µL. Histogram depicts distribution of UMIs at each condition colored by condition. Numbers within bar plot denote total UMI count within cell-containing droplets at each antibody concentration. Barcodes to the right depict cell type by color at the corresponding rank to visualize specificity of the antibody. Horizontal line depicts gating threshold for cells considered positive for the marker.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Response of individual antibodies to reduction in staining volume.</title><p>Titration plots (unique molecular identifier [UMI] count vs. cell rank) showing response to reducing staining volume from 50 µL to 25 µL. Histogram depicts distribution of UMIs at each condition colored by condition. Numbers within bar plot denote total UMI count within cell-containing droplets at each antibody concentration. Barcodes to the right depict cell type by color at the corresponding rank to visualize specificity of the antibody. Horizontal line depicts gating threshold for cells considered positive for the marker.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig3-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Reducing cell number during staining increases signal for antibodies at low concentration</title><p>To determine if the limited effect of reduced staining volume on ADT signal could be counteracted by simultaneously reducing the number of cells at the time of staining (effectively reducing the total amount of epitopes), we analyzed two PBMC samples with either 1 × 10<sup>6</sup> or 0.2 × 10<sup>6</sup> cells stained with the same concentration of antibodies (DF4) in 25 µL. Similar to reducing staining volume, the majority of the included antibodies were largely unchanged by lowering the cell density at staining, as reflected by only 8% increase in detected UMIs (from 428,680 to 462,916), and also reflected by the analogous distribution of individual markers (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>). Encouragingly, reducing the cell number at staining increased the signal from the antibodies used at low concentration and targeting highly expressed epitopes (<xref ref-type="fig" rid="fig4">Figure 4D, E</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref> and <xref ref-type="fig" rid="fig4s2">2</xref>), thus largely mitigating the loss of signal observed when the staining volume was reduced from 50 µL to 25 µL (<xref ref-type="fig" rid="fig3">Figure 3B–D</xref>). Interestingly, despite reducing the cell density at staining fivefold (from 40 to 8 × 10<sup>6</sup> cells/mL), the resulting signal did not appreciably surpass that of the sample stained in 50 µL with an intermediate cell density of 20 × 10<sup>6</sup> cells/mL (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Reducing cell number during staining increases signal for antibodies at low concentration.</title><p>Comparison of peripheral blood mononuclear cell samples stained in 25 µL antibody staining solution at dilution factor 4 at two cell densities: 1 × 10<sup>6</sup> (1000k; same sample as 25 µL in <xref ref-type="fig" rid="fig3">Figure 3</xref>) or 0.2 × 10<sup>6</sup> (200k) cells. (<bold>A</bold>) Summarized unique molecular identifier (UMI) counts within cell-containing droplets segmented by the individual antibodies colored by their concentration. (<bold>B, C</bold>) Change in antibody-derived tag signal for each antibody by reducing cell numbers at staining from 1 × 10<sup>6</sup> to 0.2 × 10<sup>6</sup> cells. Individual antibodies are colored by their concentration. Quantified by (<bold>B</bold>) sum of UMIs within cell-containing droplets assigned to each antibody and (<bold>C</bold>) 90th percentile UMI count within cell type with most abundant expression (the assayed cell type is annotated to the right). (<bold>D</bold>) Titration plot (marker UMI count vs. normalized cell rank) for CD31 signal response when reducing cell numbers at staining from 1 × 10<sup>6</sup> to 0.2 × 10<sup>6</sup> cells. Histogram depicts distribution of UMIs at each condition. Barcodes to the right depict cell-type occurrence at the corresponding rank to visualize cell specificity of the antibody. Numbers on top of the small bar plot denote total UMI count assigned to CD31 within cell-containing droplets from each condition. (<bold>E</bold>) Non-normalized UMI counts visualized on t-distributed stochastic neighbor embedding (tSNE) plot of CD31 and CD44 that are affected by the reduction in staining volume, mitigated by a concomitant reduction in cell density. Dashed line indicates the region where expression levels vary between cell densities. Titration plots for all markers can be found in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref> and <xref ref-type="fig" rid="fig4s2">2</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Response of individual antibodies to reduction in cell numbers at staining.</title><p>Titration plots (marker unique molecular identifier [UMI] count vs. cell rank) showing response to reducing cell numbers at staining from 1 × 10<sup>6</sup> to 0.2 × 10<sup>6</sup> cells. Histogram depicts distribution of UMIs at each condition colored by condition. Numbers within bar plot denote total UMI count within cell-containing droplets at each antibody concentration. Barcodes to the right depict cell type by color at the corresponding rank to visualize specificity of the antibody. Horizontal line depicts gating threshold for cells considered positive for the marker.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Response of individual antibodies to reduction in cell numbers at staining.</title><p>Titration plots (marker unique molecular identifier [UMI] count vs. cell rank) showing response to reducing cell numbers at staining from 1 × 10<sup>6</sup> to 0.2 × 10<sup>6</sup> cells. Histogram depicts distribution of UMIs at each condition colored by condition. Numbers within bar plot denote total UMI count within cell-containing droplets at each antibody concentration. Barcodes to the right depict cell type by color at the corresponding rank to visualize specificity of the antibody. Horizontal line depicts gating threshold for cells considered positive for the marker.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Fivefold reduction in cell density mitigates but does not supersede twofold reduction in staining volume.</title><p>Comparison of peripheral blood mononuclear cell samples stained in 50 µL, 25 µL, and 25 µL antibody staining solution at dilution factor 4 at cell densities: 1 × 10<sup>6</sup> (50 µL_1000k), 1 × 10<sup>6</sup> (25 µL_1000k), or 0.2 × 10<sup>6</sup> (25 µL_200k) cells, respectively. (<bold>A</bold>) Summarized unique molecular identifier (UMI) counts within cell-containing droplets segmented by the individual antibodies colored by their concentration. (<bold>B, C</bold>) Antibody-derived tag signal for each antibody at each condition. Individual antibodies are colored by their concentration. Quantified by (<bold>B</bold>) sum of UMIs within cell-containing droplets assigned to each antibody and (<bold>C</bold>) 90th percentile UMI count within cell cluster with most abundant expression (the assayed cluster is annotated to the right). (<bold>D</bold>) Titration plot (marker UMI count vs. cell rank) showing response to changing staining volume and/or cell density. Histogram depicts distribution of UMIs at each condition colored by condition. Numbers on top of the small bar plot denote total UMI count assigned to CD31 within cell-containing droplets from each sample. Barcodes to the right depict cell type by color at the corresponding rank to visualize specificity of the antibody. Horizontal line depicts gating threshold for cells considered positive for CD31.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig4-figsupp3-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Adjusting antibody concentration improves signal, lowers background, and reduces cost and sequencing requirements</title><p>To evaluate the benefits of adjusting antibody concentrations, we stained 200,000 PBMCs in a staining volume of 25 µL using the same antibody panel, with individual antibody concentrations adjusted based on their assigned categories (individual concentrations can be found in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1,</xref> and how each category was adjusted is described in <xref ref-type="table" rid="table1">Table 1</xref>). On average, the adjusted panel used 1.9-fold less antibody than the DF1 staining and 8.4-fold less than the vendor-recommended starting concentration (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Together with the reduced staining volume, this decreased antibody costs per sample to 50 USD, which is a 3.9- and 33.6-fold reduction from DF1 (195 USD) and vendor recommendations (1690 USD), respectively (based on list price of 325 USD per 10 µg; <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>).</p><p>To allow direct comparison with the DF1 sample, we integrated and down-sampled the DF1 and adjusted samples to include similar numbers cells within each cell type (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). We then down-sampled the sequenced ADT reads to yield similar UMI totals of 522,469 and 521,331 across the comparable cell populations for the DF1 and adjusted sample, respectively (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). As expected, antibodies used at reduced concentrations yielded relatively fewer UMIs (categories A and B and some from E), whereas increased concentrations yielded more (category E and some from C). Importantly, we found that antibodies with unchanged concentration yielded more UMIs at similar sequencing depth (<xref ref-type="fig" rid="fig5">Figure 5B, C</xref>). This was primarily due to a reduction of category A antibodies that accounted for 25% of the sequenced UMI sequences in the DF1 sample and only 10% in the adjusted sample.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Adjusting antibody concentrations increases signal, lowers background, and reduces costs and sequencing requirements.</title><p>(<bold>A</bold>) Single cells from the dilution factor (DF) 1 and adjusted sample were integrated and selected to yield similar number of cells within each annotated cell type, visualized by t-distributed stochastic neighbor embedding (tSNE). (<bold>B</bold>) Antibody-derived tag reads from DF1 and adjusted samples were subsampled to yield similar number of unique molecular identifiers (UMIs) within the selected cells. Size of each segment shows the distribution of UMIs among the antibodies in the panel divided into categories that determined how they were adjusted (<xref ref-type="table" rid="table1">Table 1</xref>). (<bold>C–F</bold>) Response of adjustment of individual antibodies assayed by (<bold>C</bold>) their overall sequencing usage (fraction of UMIs assigned to each marker), (<bold>D</bold>) balancing (percent of UMIs used per positive cell), (<bold>E</bold>) signal-to-noise (difference in median UMI count within positive and negative cells), and (<bold>F</bold>) background signal (percentage of UMIs used for background signal). Shapes of marker denote whether the antibody concentration was changed between the DF1 and adjusted sample. Color of ‘shapes’ denotes antibody concentration. Color of connecting lines denotes antibody category. Center line in box plot denotes the median. (<bold>G–L</bold>) Titration plot (left) and tSNE plots showing raw UMI counts (right) for antibodies in different categories. Dashed lines indicate regions of interest highlighting the differences (or lack thereof) between the DF1 and adjusted samples. Titration plots for all markers by category can be found in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplements 1</xref>–<xref ref-type="fig" rid="fig5s5">5</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Dilution factor (DF) 1 vs.adjusted antibody concentration comparisons – category A.</title><p>Titration plots (left; marker unique molecular identifier [UMI] count vs. cell rank) and t-distributed stochastic neighbor embedding (tSNE) plots colored by raw UMI counts (right) showing response to changing the antibody concentration from DF1 to the adjusted sample for markers assigned to category A. Within titration plots, histogram depicts distribution of UMIs at each condition colored by sample (and annotated with antibody concentration). Numbers within bar plot denote total UMI count within cells at each antibody concentration. Barcodes to the right depict cell type by color at the corresponding rank to visualize cell-type specificity of the antibody. Horizontal line depicts gating threshold for cells considered positive for the marker.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Dilution factor (DF) 1 vs. adjusted antibody concentration comparisons – category B.</title><p>Titration plots (left; marker unique molecular identifier [UMI] count vs. cell rank) and t-distributed stochastic neighbor embedding (tSNE) plots colored by raw UMI counts (right) showing response to changing the antibody concentration from DF1 to the adjusted sample for markers assigned to category B. Within titration plots, hHistogram depicts distribution of UMIs at each condition colored by sample (and annotated with antibody concentration). Numbers within bar plot denote total UMI count within cells at each antibody concentration. Barcodes to the right depict cell type by color at the corresponding rank to visualize cell-type specificity of the antibody. Horizontal line depicts gating threshold for cells considered positive for the marker.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig5-figsupp2-v1.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Dilution factor (DF) 1 vs. adjusted antibody concentration comparisons – category C.</title><p>Titration plots (left; marker unique molecular identifier [UMI] count vs. cell rank) and t-distributed stochastic neighbor embedding (tSNE) plots colored by raw UMI counts (right) showing response to changing the antibody concentration from DF1 to the adjusted sample for markers assigned to category C. Within titration plots, histogram depicts distribution of UMIs at each condition colored by sample (and annotated with antibody concentration). Numbers within bar plot denote total UMI count within cells at each antibody concentration. Barcodes to the right depict cell type by color at the corresponding rank to visualize cell-type specificity of the antibody. Horizontal line depicts gating threshold for cells considered positive for the marker.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig5-figsupp3-v1.tif"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 4.</label><caption><title>Dilution factor (DF) 1 vs. adjusted antibody concentration comparisons – category D.</title><p>Titration plots (left; marker unique molecular identifier [UMI] count vs. cell rank) and t-distributed stochastic neighbor embedding (tSNE) plots colored by raw UMI counts (right) showing response to changing the antibody concentration from DF1 to the adjusted sample for markers assigned to category D. Within titration plots, histogram depicts distribution of UMIs at each condition colored by sample (and annotated with antibody concentration). Numbers within bar plot denote total UMI count within cells at each antibody concentration. Barcodes to the right depict cell type by color at the corresponding rank to visualize cell-type specificity of the antibody. Horizontal line depicts gating threshold for cells considered positive for the marker.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig5-figsupp4-v1.tif"/></fig><fig id="fig5s5" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 5.</label><caption><title>Dilution factor (DF) 1 vs. adjusted antibody concentration comparisons – category E.</title><p>Titration plots (left; marker unique molecular identifier [UMI] count vs. cell rank) and t-distributed stochastic neighbor embedding (tSNE) plots colored by raw UMI counts (right) showing response to changing the antibody concentration from DF1 to the adjusted sample for markers assigned to category E. Within titration plots, histogram depicts distribution of UMIs at each condition colored by sample (and annotated with antibody concentration). Numbers within bar plot denote total UMI count within cells at each antibody concentration. Barcodes to the right depict cell type by color at the corresponding rank to visualize cell-type specificity of the antibody. Horizontal line depicts gating threshold for cells considered positive for the marker.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig5-figsupp5-v1.tif"/></fig></fig-group><p>Due to the cost of signal in these sequencing-based approaches, an optimal panel would ideally use similar number of UMIs per positive cell for each antibody (<xref ref-type="fig" rid="fig5">Figure 5D</xref>) and exhibit approximately the same positive signal (UMIs above background; <xref ref-type="fig" rid="fig5">Figure 5E</xref>). While some markers should be further reduced (such as CD4, CD45RA, CD62L, CD107a, and TCRab) and some adjustments were too extreme (such as CD14, CD19, and HLA-ABC), the adjusted sample exhibited close to a twofold increase in the median UMIs per positive cell and a 57% increase in the median positive signal (from 7 to 11 UMIs; <xref ref-type="fig" rid="fig5">Figure 5E</xref>). Importantly, all the markers with the lowest positive signal as well as number of UMIs per positive cell were all increased, reflecting a more balanced sequencing library.</p><p>Importantly, while exhibiting approximately the same relative background signal as assayed by proportion of reads within empty droplets (35–45%; data not shown), the adjusted sample generally showed much lower percentage of UMIs being assigned to background (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). This was particularly remarkable for CD86, which went from 76.5% to 12.6% and thus yielded similar positive signal while using 4.8-fold fewer UMIs (from 23,971 to 4998; <xref ref-type="fig" rid="fig5">Figure 5G</xref>). In fact, the exception to this was primarily found within category E antibodies for which concentrations were increased due to having very low UMI counts in the DF1 sample (CD56, CD127, and CD196; see <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplements 1</xref>–<xref ref-type="fig" rid="fig5s5">5</xref> for data on all markers). In these cases, the increased concentration yielded better definition of expected positive populations (<xref ref-type="fig" rid="fig5">Figure 5H</xref>). To balance the sequencing requirements of the panel, we reduced concentrations of most category B antibodies. Except CD19 (<xref ref-type="fig" rid="fig5">Figure 5I</xref>), all reduced category B antibodies showed no change in resolution of positive vs. negative populations despite a marked reduction in their UMI usage (<xref ref-type="fig" rid="fig5">Figure 5C, D</xref>) and concomitant reduction in their positive signal. For instance, when reducing anti-CD5 from 0.62 to 0.16 µg/mL, it showed largely identical distribution despite using 65% less UMIs (from 22,068 to 7740; <xref ref-type="fig" rid="fig5">Figure 5J</xref>). Category C and E antibodies showed consistently increased positive signal (<xref ref-type="fig" rid="fig5">Figure 5D</xref>) and consequently allowed better identification of populations known to express these markers, such as naive T cells and monocytes for CD45RA and CD45RO, respectively (<xref ref-type="fig" rid="fig5">Figure 5K, L</xref>).</p></sec><sec id="s2-5"><title>Background signal from oligo-conjugated antibodies is dependent on antibody concentration and abundances of epitopes</title><p>Free-floating antibodies in the solution have been shown to be one of the major contributors to background signal for ADTs (<xref ref-type="bibr" rid="bib16">Mulè et al., 2020</xref>). Similar to cell-free RNA, background ADT signal can be assayed from empty droplets. To determine the background signal of the different antibodies in our panel, we split the captured barcodes into cell-containing and empty droplets based on the inflection point of the barcode-rank plot for the gene expression UMI counts (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Despite being a ‘super-loaded’ 10X Chromium run targeting 20,000 cells, the number of empty droplets vastly outnumbered the cell-containing droplets. Consequently, several antibodies exhibited more cumulated UMIs within empty droplets than within cell-containing droplets (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). This was particularly prevalent within antibodies used at concentration of or above 2.5 µg/mL, thus drastically skewing the frequency of these antibodies within the empty droplets as compared with cell-containing droplets (<xref ref-type="fig" rid="fig6">Figure 6A, B</xref>). Conversely, antibodies targeting highly abundant epitopes were enriched within cell-containing droplets, irrespective of their staining concentration (such as CD44 and CD107a, HLA-ABC, HLA-DR; <xref ref-type="fig" rid="fig6">Figure 6C</xref>). This was consistent with publicly available datasets where ADTs from antibodies targeting abundant epitopes (such as CD3, CD4, CD8, and CD45RA) were enriched within the cell-containing droplets using two different capture approaches (3′- and 5′ capture; <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>). We found that ADT signal in empty droplets (i.e., background) was highly correlated with the UMI cutoff for detection (<xref ref-type="fig" rid="fig6">Figure 6D</xref>, <xref ref-type="fig" rid="fig6s3">Figure 6—figure supplements 3</xref> and <xref ref-type="fig" rid="fig6s4">4</xref>). Markers with low background generally showed low UMI cutoff and exhibited high dynamic range, allowing identification of multiple levels of expression (as seen for CD4 and CD19; <xref ref-type="fig" rid="fig6">Figure 6D, E</xref>). In contrast, markers with high background showed high UMI cutoff regardless of whether they exhibited cell-type-specific signal (such as CD86 and CD279; <xref ref-type="fig" rid="fig6">Figure 6F</xref>) or whether their positive signal was absent or obscured by the high background (such as TCRγδ; <xref ref-type="fig" rid="fig6">Figure 6G</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Background signal from oligo-conjugated antibodies is dependent on concentration and presence of epitopes.</title><p>Signal from free-floating antibodies in the cell suspension is a major source of background in droplet-based scRNA-seq and can be assayed by their signal within non-cell-containing (empty) droplets. (<bold>A, B</bold>) Comparison of signal from each antibody within cell-containing and empty droplets (identified in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>) by (<bold>A</bold>) their total unique molecular identifier (UMI) counts or (<bold>B</bold>) their relative frequency within each compartment. Color bar denotes antibody concentration at dilution factor 1 (DF1). (<bold>C</bold>) Ratio of UMI frequencies of each marker between cell-containing and empty droplets. Markers with black bars have greater frequency in cell-containing droplets, whereas gray bars have greater frequency in empty droplets. (<bold>D</bold>) UMI thresholds for detection above-background for each marker within peripheral blood mononuclear cells and lung tumor samples (based on gating in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). (<bold>E–G</bold>) Examples of t-distributed stochastic neighbor embedding (tSNE) plots showing non-normalized (raw) UMI counts from cells stained at DF1 for (<bold>E</bold>) markers with low background, (<bold>F</bold>) markers with high background that still exhibit cell-type-specific signal (CD86 and CD279), and (<bold>G</bold>) markers where positive signal is absent or obscured by the background. Regions of background signal are encircled by dashed lines. To make the color scale in the tSNE plots less sensitive to extreme values, we set the upper threshold to the 90% percentile. tSNE plots for all markers can be found in <xref ref-type="fig" rid="fig6s3">Figure 6—figure supplements 3</xref> and <xref ref-type="fig" rid="fig6s4">4</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Quantifying unique molecular identifiers (UMIs) within cells and empty droplets of antibody-derived tag (ADT) and hashtag-oligo (HTO).</title><p>Knee plots (barcode rank vs. total UMIs within barcode) for mRNA, ADT, and HTO libraries. Cell-containing droplets were filtered based on the total UMI count at the inflection point in the mRNA plot. Red lines depict the position of rank 18039, largely corresponding to the cutoff for cell-containing droplets.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Quantifying unique molecular identifiers (UMIs) within cell-containing and empty droplets from public 10X datasets.</title><p>(<bold>A</bold>) Knee plots (barcode rank vs. total UMIs within barcode) for mRNA libraries within three publicly available single-cell RNA sequencing runs (from the 10X Genomics website) showing filtering of cell-containing and empty droplets based on the total UMI count at the inflection point. (<bold>B</bold>) Total UMI counts for the individual antibodies from each of the antibody-derived tag libraries within cell-containing and empty droplets.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig6-figsupp2-v1.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 3.</label><caption><title>Cellular distribution of ADT signal visualized by t-distributed stochastic neighbor embedding (tSNE) plots displaying raw (unnormalized) UMI counts from the cells stained at dilution factor 1 for each antibody.</title><p>To make the color scale less sensitive to outliers, we set upper threshold at the 90% percentile.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig6-figsupp3-v1.tif"/></fig><fig id="fig6s4" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 4.</label><caption><title>Cellular distribution of ADT signal visualized by t-distributed stochastic neighbor embedding (tSNE) plots displaying raw (unnormalized) UMI counts from the cells stained at dilution factor 1.</title><p>To make the color scale less sensitive to outliers, we set upper threshold at the 90% percentile.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-fig6-figsupp4-v1.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, we show that titration of oligo-conjugated antibodies for multimodal single-cell analysis can improve sensitivity, lower background signal, and reduce costs and sequencing requirements, and that such optimizations go beyond (and even against) the need to reach the ‘saturation plateau’. We show that for a representative panel of 52 antibodies, most antibodies used in concentrations at or above 2.5 µg/mL show high background signal and we observed minimal loss in sensitivity upon a fourfold reduction in concentration of these antibodies. Antibodies used at concentrations between 0.625 and 2.5 µg/mL show limited (nonlinear) response, whereas most antibodies used at concentrations below 0.625 µg/mL show linear or close to linear response. It should be noted that these estimates may be inherently biased given that the starting concentrations were based on our prior experience with the individual antibody clones and our assumptions regarding abundance of targeted epitopes. This has favored using higher concentrations for antibodies known to have low performance and for antibodies with unknown performance. Nonetheless, for antibodies with unknown performance, our results highlight the benefits of conducting titration experiments or initially using the antibodies at concentrations in the 0.625–2.5 µg/mL range, rather than the 5–10 µg/mL range recommended by published antibody staining protocols and by commercial vendors. This is particularly important when adding new antibodies to existing panels, where antibodies added in a high concentration may account for a disproportionate usage of the total sequencing reads without providing any biological information (as seen for CD86, CD152, CD183, CD197, and TCRγδ in the DF1 panel). Our results also show that concentrations of antibodies targeting highly expressed epitopes can be further reduced without affecting resolution of positive and negative cells, even when these antibodies are already used within their linear concentration range (such as CD5, CD8, and CD19). By reducing the concentration of these antibodies, the allocation of reads to each antibody becomes more balanced between epitopes present at disparate abundance, allowing the overall sequencing depth to be reduced and maximizing the yield of a sequencing run.</p><p>By using varying starting concentrations based on prior experience and titrating the full panel together, our study does not necessarily identify optimal concentrations of individual antibodies. This could have been achieved by using saturating starting concentrations and additional serial dilutions, as has been previously done for a few markers (<xref ref-type="bibr" rid="bib22">Stoeckius et al., 2018</xref>). However, due to the cost of signal in these cytometry-by-sequencing methods, using all antibodies at their highest signal-to-noise ratios would require much deeper sequencing as highly expressed markers would use the vast majority of the total sequencing reads. Instead, we aimed to get sufficient signal-to-noise, while keeping the sequencing allocated to each marker balanced. A further complication for titration experiments that start with saturating amounts of antibody is the observation that background signal can be largely attributed to free-floating antibodies in the solution. Thus, using high concentrations for all markers in one or more sample would increase the background in all samples if these were multiplexed into the same droplet segregation. This would likely obscure the positive signals and possibly titration response at lower concentrations (similar to what we see for category A antibodies). To avoid this, each condition would have to be run in its own droplet segregation, making traditional titration experiments prohibitively costly.</p><p>In this study, we used commercially available antibody clones that have been extensively used for other applications such as flow and mass cytometry, and we do see high concordance between ADT signals and the expected antigens within each cell type. Our approach did not allow us to formally test whether each antibody is specific to its intended antigen as we inferred specificity based on our understanding of the included cell types and looked for concordance with gene expression signature of the cells. However, it should be noted, that when using antibody clones that are unfamiliar or have not undergone extensive testing, it is important to assure their specificity.</p><p>Reducing staining volume for 10<sup>6</sup> PBMCs from 50 µL to 25 µL only showed a minor effect on signal, and this minimal impact was primarily observed for antibodies used at very low concentrations (0.0125–0.025 µg/mL) targeting highly expressed epitopes (such as CD31, CD44, and CD45). This effect was readily counteracted by concomitantly reducing the number of cells at staining to 0.2 × 10<sup>6</sup> PBMCs in 25 µL. In flow cytometry, while the binding of antibody is strictly dependent on its concentration, background signal is dependent on the ratio between the total amounts of antibody and epitopes (<xref ref-type="bibr" rid="bib8">Hulspas, 2010</xref>). Consequently, background can be reduced by increasing the number of cells (increasing the amount of epitope) or decreasing staining volume (effectively reducing the amount of antibody without changing its concentration). For antibodies optimized to reach their ‘saturation plateau’ (common in flow cytometry), both of these approaches can be applied without changing the true signal. In contrast, for oligo-conjugated antibodies used in sequencing-based single-cell approaches, operating in the linear range, signal from highly abundant epitopes stained with low concentration of antibody will be affected. In such cases, the cells can be stained in multiple steps adjusting the staining volume while keeping the concentration the same – that is, staining in a smaller volume for antibodies with high background and subsequently staining antibodies at low concentration in a higher volume. In this regard, when multiplexing samples, pre-staining each sample with hashtags and pooling prior to staining with additional CITE-seq antibodies may provide multiple advantages: (1) all samples are stained at the same time with the exact same antibody mixture – making cross-sample comparison more accurate, (2) by having more cells in a smaller total volume, less total antibody is used in the presence of more epitopes conceivably reducing the background signal and (3) samples where cell number at staining is a limiting factor, such as small tissue biopsies, will be exposed to the same local concentrations of antibody as more abundant samples (such as PBMCs) removing potential differences between samples by antibodies being ‘sponged’ by differences in overall epitope abundance. However, this approach is only available when all samples are similarly affected by the staining procedure and can tolerate the additional washes needed (after both hashing and CITE-seq staining).</p><p>We compared ADT signal from PBMCs stained with the same antibody panel at the starting concentration with a sample stained at concentrations adjusted following the titration experiment. While some markers could benefit from further adjustments, the sample stained with the adjusted panel was more balanced in its distribution of sequencing reads among markers, having twice the median UMIs per positive cell. Despite intentionally reducing signal in category B antibodies, we found an overall 57% increase in the median positive signal. Concomitantly, the adjusted panel exhibited 43% lower background signal (median of 26.3% to 14.9% UMIs assigned to background) despite increasing the concentrations of many category C and E antibodies. Consequently, the adjusted concentrations greatly improved the overall performance of the panel. We took precautions to make the samples as comparable as possible by down-sampling the sequencing depth to the same level and comparing similar numbers of analogouscells (at the mRNA level). Nonetheless, as these samples were from different preparations and different donors, we cannot exclude that some of the observed differences can be attributed to these factors. For instance, we found that the monocytes in the adjusted sample exhibited higher nonspecific binding (as seen from the isotype controls) than in the DF1 sample, despite being treated with the same concentrations of Fc-blocking reagents (which should minimize such biding; <xref ref-type="bibr" rid="bib1">Andersen et al., 2016</xref>).</p><p>Due to the 10- to 1000-fold higher numbers of individual proteins as compared to mRNA (<xref ref-type="bibr" rid="bib12">Marguerat et al., 2012</xref>), ADT libraries have high library complexity (unique UMI content) and are rarely sequenced near saturation. Thus, either sequencing deeper or squandering less reads on a few antibodies increases signal from all (other) included antibodies. We found that by simply reducing the concentration of the five antibodies used at 10 µg/mL, we gained 17% more reads for the remaining antibodies. Consequently, assuming we are satisfied with the magnitude of signal we got from all other antibodies using the starting concentration, this directly translates to a 17% reduction in sequencing costs. Due to different antibodies being adjusted in different directions for different reasons (according to their assigned categories), it is difficult to convert the overall improved utilization of sequencing reads into exact savings calculation. However, assuming signal is improved or unchanged, the savings on sequencing for each marker can be estimated by how many UMIs are needed to acquire a given signal. In the case of CD86, we found that the signal was dramatically improved by reducing concentration from 10 to 0.667 µg/mL while also using 79% fewer UMIs and consequently a much lower number of sequencing reads.</p><p>Empty droplets have been shown to be useful for determining the background signal of CITE-seq (<xref ref-type="bibr" rid="bib16">Mulè et al., 2020</xref>). This suggests that the major source of background signal for ADT libraries can be attributed to free-floating antibodies (or oligos) in the solution rather than nonspecific antibody binding to cell surfaces. In the present study, the samples were multiplexed by hashing antibodies, pooled after oligo-conjugated antibody staining, and then run in the same 10X Chromium lane. This obscures the contribution of each sample to the total amount of free-floating antibodies in the final cell suspension, which is conceivably skewed towards the samples stained in high volume with the highest concentration of antibodies. Consequently, as free-floating antibodies are the major source of background, this would explain why we do not observe reduced background in the cells stained at the lowest concentrations (i.e., DF4). As such, for markers with no specific signal due to high background (such as CD183, CD197, and TCRgd), the titration responses may be underestimated due to specific signal being lost within the high background. This also means, that for markers with high background signal our proposed reductions in concentrations are conservative as we would expect to see decreased background in samples stained with reduced amount of antibodies (as seen in the comparison with the adjusted concentrations). In droplet-based single-cell analyses, background signal is not only diminishing the sensitivity and resolution of true signals, but is also a major contributor to sequencing cost of ADT libraries. Due to empty droplets vastly outnumbering cell-containing droplets, we found that ADT signal from empty droplets can easily account for 20–50% of the total sequencing reads and consequently 20–50% of the sequencing cost. The number of antibodies used in CITE-seq-related platforms is only expected to expand. Additionally, the number of cells included in each experiment is continuously being increased (as seen for methods such as SCITO-seq; <xref ref-type="bibr" rid="bib9">Hwang, 2020</xref>). As such, reducing background signal from oligo-conjugated antibodies should be a priority. The source of the free-floating antibodies is not completely understood. Observations from this study suggest that antibodies used at high concentration targeting absent or sparse epitopes are highly enriched within the empty droplets, as compared to the cell-containing droplets. This indicates that residual unbound antibody from the staining step is a major contributor despite several washing steps. Practically, this suggests that additional washing after cell staining would be beneficial when the number and type of cells in the samples allow it. Optimal washing is achieved by repeated washing steps while assuring that maximal residual supernatant is removed after each centrifugation and followed by gentle but complete resuspension in a large buffer volume.</p><p>More and more advanced CITE-seq-related cytometry-by-sequencing platforms are rapidly being developed. However, while these platforms utilize different methods to assure single-cell resolution and use different approaches to label the cells, they all use high-throughput sequencing to count signal from a variety of oligo-conjugated probes (such as antibodies with both surface and intracellular targets, MHC-peptide multimers, and B-cell receptor antigens) (<xref ref-type="bibr" rid="bib21">Stoeckius et al., 2017</xref>; <xref ref-type="bibr" rid="bib19">Peterson et al., 2017</xref>; <xref ref-type="bibr" rid="bib9">Hwang, 2020</xref>; <xref ref-type="bibr" rid="bib20">Setliff et al., 2019</xref>; <xref ref-type="bibr" rid="bib17">O'Huallachain et al., 2020</xref>; <xref ref-type="bibr" rid="bib18">Overall et al., 2020</xref>; <xref ref-type="bibr" rid="bib4">Gaublomme et al., 2019</xref>; <xref ref-type="bibr" rid="bib10">Katzenelenbogen et al., 2020</xref>). Most of the observations and conclusions from this study will be applicable to tthese platforms, where improving oligo-conjugated probe signal is critical to their utility and economic feasibility.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Clinical samples</title><p>Lung adenocarcinoma patient sample (female, 57 years old, former smoker: 15 pack-years, treated with chemotherapy) was collected at New York University Langone Health Medical Center in accordance with protocols approved by the New York University School of Medicine Institutional Review Board and Bellevue Facility Research Review Committee (IRB#: i15-01162 and S16-00122).</p></sec><sec id="s4-2"><title>Cell isolation, cryopreservation, and thawing</title><p>PBMCs were isolated from a leukopak and whole blood from healthy donors (New York Blood Center) for the pre-titration and adjusted samples, respectively. PBMCs were purified by diluting in PBS and subsequent gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare) and 50 mL conical tubes (Falcon). PBMCs in the interphase were collected and washed twice with PBS containing 2% FBS. Lung tumor sample were cut into small pieces with a razor blade and enzymatically digested (100 U/mL Collagenase IV, Sigma-Aldrich, C5138-1G; 50 µg/mL DNase 1, Worthington, LS002138) for 35 min being rotated at 37°C in HEPES buffered RPMI 1640 containing 0.5% FBS. After digestion, the sample was forced through a 100 µm cell strainer to make a single-cell suspension. Single-cell suspensions from both PBMCs and lung tumor were cryopreserved in freezing medium (40% RPMI 1640, 50% FBS, and 10% DMSO) and stored in liquid nitrogen. On the day of the experiments, cryopreserved samples were thawed for 1–2 min in a 37°C water bath, washed twice in warm PBS containing 2% FBS, and resuspended in complete media (RPMI 1640 supplemented with 10% FBS and 2 mM L-Glut).</p></sec><sec id="s4-3"><title>Oligo-conjugated antibody staining</title><p>We modified the published protocol for ECCITE-seq (<xref ref-type="bibr" rid="bib14">Mimitou et al., 2019</xref>) to stain cells in round-bottom 96-well plates (as is common practice for flow cytometry staining in many laboratories). This allowed us to reduce staining volumes and centrifugation time analogous to staining for flow cytometry. After thawing, the intended number of cells was resuspended in 12.5 µL or 25 µL of CITE-seq staining buffer (2% BSA, 0.01% Tween in PBS) for samples stained in a total of 25 µL or 50 µL, respectively. To prevent antibody binding to Fc receptors (<xref ref-type="bibr" rid="bib1">Andersen et al., 2016</xref>), Fc receptor block from two vendors (TruStain FcX, BioLegend, and FcR blocking reagent, Miltenyi) was added to the suspension and incubated for 10 min on ice. During incubation, the antibody solution of 52 TotalSeqC antibodies (BioLegend; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) was washed on a pre-wet Amicon Ultra-0.5 Centrifugal Filter to remove sodium azide. The volume of the resulting antibody pool was adjusted to 2× of final concentrations and 12.5 µL or 25 µL was added to the cells to achieve a total staining volume of 25 µL or 50 µL, respectively. 10 µg/mL of a unique hashing antibody was added to each sample and incubated for 30 min on ice. After staining, cells were washed four times in 1 × 150 µL and 3 × 200 µL CITE-seq staining buffer.</p></sec><sec id="s4-4"><title>Super-loading of 10X Chromium</title><p>Individually hashed samples were counted using a hemocytometer and pooled in equal ratio at high concentration. Pooled sample was strained through a 70 µm cell strainer and counted again using a hemocytometer. To achieve approximately 20,000 cells after doublet removal, cell concentration was adjusted to 1314 cells/µL to achieve the target of 41,645 cells in 31.7 µL for super-loading of the 10X Chromium Chip A. Gene expression (using 5′ v1 chemistry; 10X Genomics) and ADT and hashtag-oligo (HTO) libraries were constructed using reagents, primers, and protocol from the published ECCITE-seq protocol (<xref ref-type="bibr" rid="bib14">Mimitou et al., 2019</xref>). All libraries from the titration run were sequenced together with other samples on an Illumina NovaSeq6000 S1 flow cell. The post-titration (adjusted) sample (using 5′ v1.1 chemistry; 10X Genomics) was multiplexed and sequenced together with other samples not included in this study on Illumina NovaSeq6000 SP and S1 flow cells.</p></sec><sec id="s4-5"><title>Alignment and counting of single-cell sequencing libraries</title><p>The multiplexed gene expression library was aligned using kallisto (v0.46)-bustools (v0.39.0) (<xref ref-type="bibr" rid="bib13">Melsted et al., 2021</xref>). Given the polyA selection inherent in the 10X Genomics protocol, reads were aligned against a reference transcriptome based on the GTF file included in the Cell Ranger software (refdata-cellranger-GRCh38-3.0.0/genes/genes.gtf; 10X Genomics) that does not include as many non-polyA transcripts as the human transcriptome included by kallisto-bustools by default. From the 77,507,446 reads assigned to the gene expression library, 66.9% aligned to the transcriptome. ADT and HTO libraries were counted using the <italic>kallisto indexing and tag extraction</italic> (KITE) workflow (<ext-link ext-link-type="uri" xlink:href="https://github.com/pachterlab/kite">https://github.com/pachterlab/kite</ext-link>), resulting in 82,527,351 and 65,875,774 counted reads, respectively. Number of UMIs and genes detected per cell across cell lineages can be found in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A, B</xref>.</p></sec><sec id="s4-6"><title>Single-cell demultiplexing, preprocessing, and down-sampling</title><p>To allow detection of UMI counts within non-cell-containing droplets, unfiltered count matrices from each modality were loaded into a ‘Seurat’ (v3.1.4) object (<xref ref-type="bibr" rid="bib23">Stuart et al., 2019</xref>). Samples were demultiplexed by their unique HTO using the Seurat function ‘MULTIseqDemux’ yielding 19,560 demultiplexed cells. This allowed the removal of 3724 (19%) cross-sample doublets. Due to the shallow sequencing of the mRNA library (~4000 reads/cell), expression of at least 60 genes and a percent mitochondrial reads below 15% were used to remove barcodes from non-viable cells or debris (2499 or 15% of cells removed). Intra-sample doublets were removed using the ‘scDblFinder’ (v1.1.8) R package (392 cells removed). UMI counts from ADTs were normalized using default configuration of the DSB (v0.1.0) R package with ADT signal from HTO-negative droplets used as empty drop matrix and using included isotype controls. Gene expression was preprocessed using the default Seurat v3 pipeline, and fine-grained clusters were identified using the ‘FindClusters’ function with a resolution of 1.2. Clusters were annotated by lineages and cell types using their distinct expression of markers within the mRNA or ADT modality and aided by cell-by-cell annotation from the SingleR R package (v1.4.0) using the ‘Monaco reference’ from the celldex R package (v1.0.0) made from bulk RNA-seq samples of sorted immune cell populations from GSE107011 (<xref ref-type="bibr" rid="bib15">Monaco et al., 2019</xref>). Top five differentially expressed marker genes for each cluster can be found in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>. To allow direct comparison of UMI counts across conditions, each condition was down-sampled by tissue of origin to include the same number of cells within each fine-grained cell-type cluster (resulting in 1777 cells from each PBMC sample and 1681 cells from each lung tumor sample).</p></sec><sec id="s4-7"><title>Integration and sub-sampling for pre- and post-titration comparison</title><p>The post-titration (adjusted) sample was pre-processed as described above. Together with the DF1 sample, the adjusted sample was normalized and integrated based on their mRNA expression using the SCTransform and IntegrateData functions from the Seurat package as described in the Seurat integration vignette (<xref ref-type="bibr" rid="bib23">Stuart et al., 2019</xref>; <xref ref-type="bibr" rid="bib6">Hafemeister and Satija, 2019</xref>). After mRNA-based clustering using FindClusters at resolution 1.2, similar number of comparable cells was selected by taking the nearest neighbors in PCA-space for each cell in the sample with the fewest cells within the given cluster. This sampling assured that similar number of comparable cells (at the mRNA level) were selected for comparison, thus minimizing the effect of the sample differences. To allow direct comparison of UMI counts and eliminate differences in sequencing depth as a factor, we down-sampled the FASTQ files from the ADT modality of the adjusted sample to achieve similar totals of UMIs within the DF1 (522,469) and adjusted (521,331) samples.</p></sec><sec id="s4-8"><title>Comparing ADT signal from cell-containing and empty droplets</title><p>For comparison of UMI counts within cell-containing and non-cell-containing (empty) droplets for the present dataset and the 10X Genomics datasets, we divided the unfiltered count matrices by the inflection point in their ranked per cell UMI sum from the mRNA library. Barcodes above the inflection point were then used to extract UMI counts within cell-containing droplets from each antibody oligo modality. All UMIs that were not included in cell-containing droplets were considered from empty droplets.</p></sec><sec id="s4-9"><title>Data and code availability</title><p>All codes and commands used to process the data and generate all plots and figures are available at GitHub: <ext-link ext-link-type="uri" xlink:href="https://github.com/Terkild/CITE-seq_optimization">https://github.com/Terkild/CITE-seq_optimization </ext-link> (<xref ref-type="bibr" rid="bib3">Buus, 2021</xref>; copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:2f09a1f62c7ff5747082d3df35ba084de2c74118;origin=https://github.com/Terkild/CITE-seq_optimization;visit=swh:1:snp:0ee750838031765e942353cfad04eb17b54b142d;anchor=swh:1:rev:1c7fcabb18a1971dc4d6e29bc3ed4f6f36b2361f/">swh:1:rev:1c7fcabb18a1971dc4d6e29bc3ed4f6f36b2361f</ext-link>).</p><p>UMI count matrices from the optimization experiment have been deposited at FigShare with DOI: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.c.5018987">https://doi.org/10.6084/m9.figshare.c.5018987</ext-link>. The feature barcode 3′ and 5′ VDJ 10X datasets are available from the 10X Genomics website.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>Work in Dr. Koralov’s laboratory was supported by the NIH R01 grant (HL-125816), LEO Foundation Grant (LF-OC-20–000351), NYU Cancer Center Pilot Grant (P30CA016087), the Judith and Stewart Colton Center for Autoimmunity Pilot grant, and a grant from the Drs. Martin and Dorothy Spatz Foundation. TBB and NØ are supported by the Danish Cancer Society (Kræftens Bekæmpelse), the Danish Council for Independent Research (Danmarks Frie Forskningsfond), and the LEO Foundation. We thank the NYU Genome Technology Center for technical assistance and support and acknowledge the NYU Center for Biospecimen Research and Development and NYU Perlmutter Cancer Center for their support in acquiring patient biospecimens.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>is co-inventor of a patent related to the single cell technology utilized in this study (US provisional patent application 62/515-180).</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Investigation, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Investigation, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Resources, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Software, Visualization, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Resources, Data curation, Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Resources, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Supervision, Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Funding acquisition, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Human subjects: Lung adenocarcinoma patient sample was collected at New York University Langone Health Medical Center in accordance with protocols approved by the New York University School of Medicine Institutional Review Board and Bellevue Facility Research Review Committee (IRB#: i15-01162 and S16-00122).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Antibody panel and concentrations. Table of the 52 antibodies included in the panel.</title><p>Also contains individual clones and concentrations used for the different conditions included in the study.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-61973-supp1-v1.docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Antibody cost calculations.</title><p>Antibody costs of the 52 antibody panel using vendor recommendations for staining volume and concentrations, pre-titration (dilution factor 1) concentrations, and adjusted concentrations.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-61973-supp2-v1.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-61973-transrepform-v1.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All code and commands used to process the data and to generate all plots and figures are available at GitHub: <ext-link ext-link-type="uri" xlink:href="https://github.com/Terkild/CITE-seq_optimization">https://github.com/Terkild/CITE-seq_optimization</ext-link> and a copy is archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:rev:1c7fcabb18a1971dc4d6e29bc3ed4f6f36b2361f/">https://archive.softwareheritage.org/swh:1:rev:1c7fcabb18a1971dc4d6e29bc3ed4f6f36b2361f/</ext-link>. UMI count matrices from the optimization experiment have been deposited at FigShare with <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.c.5018987">https://doi.org/10.6084/m9.figshare.c.5018987</ext-link>. The feature barcode 3' and 5' VDJ 10X datasets are available from the 10X Genomics website.</p><p>The following dataset was generated:</p><p><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Buus</surname><given-names>TB</given-names></name><name><surname>Herrera</surname><given-names>A</given-names></name><name><surname>Ivanova</surname><given-names>E</given-names></name><name><surname>Mimitou</surname><given-names>E</given-names></name><name><surname>Cheng</surname><given-names>A</given-names></name><name><surname>Herati</surname><given-names>R</given-names></name><name><surname>Papagiannakopoulos</surname><given-names>T</given-names></name><name><surname>Smibert</surname><given-names>P</given-names></name><name><surname>Ødum</surname><given-names>N</given-names></name><name><surname>Koralov</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Improving oligo-conjugated antibody signal in multimodal single-cell analysis</data-title><source>figshare</source><pub-id assigning-authority="figshare" pub-id-type="doi">10.6084/m9.figshare.c.5018987.v1</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname> <given-names>MN</given-names></name><name><surname>Al-Karradi</surname> <given-names>SNH</given-names></name><name><surname>Kragstrup</surname> <given-names>TW</given-names></name><name><surname>Hokland</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Elimination of erroneous results in flow cytometry caused by antibody binding to fc receptors on human monocytes and macrophages</article-title><source>Cytometry Part A</source><volume>89</volume><fpage>1001</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1002/cyto.a.22995</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Au-Yeung</surname> <given-names>A</given-names></name><name><surname>Takahashi</surname> <given-names>C</given-names></name><name><surname>Mathews</surname> <given-names>WR</given-names></name><name><surname>O'Gorman</surname> <given-names>WE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Visualization of mass cytometry signal background to enable optimal core panel customization and signal threshold gating</article-title><source>Methods in Molecular Biology</source><volume>1989</volume><fpage>35</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-9454-0_3</pub-id><pub-id pub-id-type="pmid">31077097</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Buus</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>CITE-seq_optimization</data-title><source>Software Heritage</source><version designator="swh:1:rev:1c7fcabb18a1971dc4d6e29bc3ed4f6f36b2361f">swh:1:rev:1c7fcabb18a1971dc4d6e29bc3ed4f6f36b2361f</version><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:2f09a1f62c7ff5747082d3df35ba084de2c74118;origin=https://github.com/Terkild/CITE-seq_optimization;visit=swh:1:snp:0ee750838031765e942353cfad04eb17b54b142d;anchor=swh:1:rev:1c7fcabb18a1971dc4d6e29bc3ed4f6f36b2361f/">https://archive.softwareheritage.org/swh:1:dir:2f09a1f62c7ff5747082d3df35ba084de2c74118;origin=https://github.com/Terkild/CITE-seq_optimization;visit=swh:1:snp:0ee750838031765e942353cfad04eb17b54b142d;anchor=swh:1:rev:1c7fcabb18a1971dc4d6e29bc3ed4f6f36b2361f/</ext-link></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaublomme</surname> <given-names>JT</given-names></name><name><surname>Li</surname> <given-names>B</given-names></name><name><surname>McCabe</surname> <given-names>C</given-names></name><name><surname>Knecht</surname> <given-names>A</given-names></name><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Drokhlyansky</surname> <given-names>E</given-names></name><name><surname>Van Wittenberghe</surname> <given-names>N</given-names></name><name><surname>Waldman</surname> <given-names>J</given-names></name><name><surname>Dionne</surname> <given-names>D</given-names></name><name><surname>Nguyen</surname> <given-names>L</given-names></name><name><surname>De Jager</surname> <given-names>PL</given-names></name><name><surname>Yeung</surname> <given-names>B</given-names></name><name><surname>Zhao</surname> <given-names>X</given-names></name><name><surname>Habib</surname> <given-names>N</given-names></name><name><surname>Rozenblatt-Rosen</surname> <given-names>O</given-names></name><name><surname>Regev</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Nuclei multiplexing with barcoded antibodies for single-nucleus genomics</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2907</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10756-2</pub-id><pub-id pub-id-type="pmid">31266958</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gullaksen</surname> <given-names>S‐E</given-names></name><name><surname>Bader</surname> <given-names>L</given-names></name><name><surname>Hellesøy</surname> <given-names>M</given-names></name><name><surname>Sulen</surname> <given-names>A</given-names></name><name><surname>Fagerholt</surname> <given-names>OHE</given-names></name><name><surname>Engen</surname> <given-names>CB</given-names></name><name><surname>Skavland</surname> <given-names>J</given-names></name><name><surname>Gjertsen</surname> <given-names>BT</given-names></name><name><surname>Gavasso</surname> <given-names>S</given-names></name><name><surname>Gullaksen</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Titrating complex mass cytometry panels</article-title><source>Cytometry Part A</source><volume>95</volume><fpage>792</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1002/cyto.a.23751</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hafemeister</surname> <given-names>C</given-names></name><name><surname>Satija</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression</article-title><source>Genome Biology</source><volume>20</volume><elocation-id>296</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-019-1874-1</pub-id><pub-id pub-id-type="pmid">31870423</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hulspas</surname> <given-names>R</given-names></name><name><surname>O'Gorman</surname> <given-names>MRG</given-names></name><name><surname>Wood</surname> <given-names>BL</given-names></name><name><surname>Gratama</surname> <given-names>JW</given-names></name><name><surname>Sutherland</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Considerations for the control of background fluorescence in clinical flow cytometry</article-title><source>Cytometry Part B: Clinical Cytometry</source><volume>76B</volume><fpage>355</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1002/cyto.b.20485</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hulspas</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Titration of fluorochrome-conjugated antibodies for labeling cell surface markers on live cells</article-title><source>Current Protocols in Cytometry</source><volume>6</volume><elocation-id>29</elocation-id><pub-id pub-id-type="doi">10.1002/0471142956.cy0629s54</pub-id><pub-id pub-id-type="pmid">20938920</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Hwang</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SCITO-seq: single-cell combinatorial indexed cytometry sequencing</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.03.27.012633</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katzenelenbogen</surname> <given-names>Y</given-names></name><name><surname>Sheban</surname> <given-names>F</given-names></name><name><surname>Yalin</surname> <given-names>A</given-names></name><name><surname>Yofe</surname> <given-names>I</given-names></name><name><surname>Svetlichnyy</surname> <given-names>D</given-names></name><name><surname>Jaitin</surname> <given-names>DA</given-names></name><name><surname>Bornstein</surname> <given-names>C</given-names></name><name><surname>Moshe</surname> <given-names>A</given-names></name><name><surname>Keren-Shaul</surname> <given-names>H</given-names></name><name><surname>Cohen</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>SY</given-names></name><name><surname>Li</surname> <given-names>B</given-names></name><name><surname>David</surname> <given-names>E</given-names></name><name><surname>Salame</surname> <given-names>TM</given-names></name><name><surname>Weiner</surname> <given-names>A</given-names></name><name><surname>Amit</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Coupled scRNA-Seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in Cancer</article-title><source>Cell</source><volume>182</volume><fpage>872</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.06.032</pub-id><pub-id pub-id-type="pmid">32783915</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mair</surname> <given-names>F</given-names></name><name><surname>Erickson</surname> <given-names>JR</given-names></name><name><surname>Voillet</surname> <given-names>V</given-names></name><name><surname>Simoni</surname> <given-names>Y</given-names></name><name><surname>Bi</surname> <given-names>T</given-names></name><name><surname>Tyznik</surname> <given-names>AJ</given-names></name><name><surname>Martin</surname> <given-names>J</given-names></name><name><surname>Gottardo</surname> <given-names>R</given-names></name><name><surname>Newell</surname> <given-names>EW</given-names></name><name><surname>Prlic</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A targeted Multi-omic analysis approach measures protein expression and Low-Abundance transcripts on the Single-Cell level</article-title><source>Cell Reports</source><volume>31</volume><elocation-id>107499</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.03.063</pub-id><pub-id pub-id-type="pmid">32268080</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marguerat</surname> <given-names>S</given-names></name><name><surname>Schmidt</surname> <given-names>A</given-names></name><name><surname>Codlin</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name><name><surname>Aebersold</surname> <given-names>R</given-names></name><name><surname>Bähler</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Quantitative analysis of fission yeast transcriptomes and proteomes in proliferating and quiescent cells</article-title><source>Cell</source><volume>151</volume><fpage>671</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.09.019</pub-id><pub-id pub-id-type="pmid">23101633</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melsted</surname> <given-names>P</given-names></name><name><surname>Booeshaghi</surname> <given-names>AS</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Modular, efficient and constant-memory single-cell RNA-seq preprocessing</article-title><source>Nature Biotechnology</source><volume>1</volume><elocation-id>00870-2</elocation-id><pub-id pub-id-type="doi">10.1038/s41587-021-00870-2</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mimitou</surname> <given-names>EP</given-names></name><name><surname>Cheng</surname> <given-names>A</given-names></name><name><surname>Montalbano</surname> <given-names>A</given-names></name><name><surname>Hao</surname> <given-names>S</given-names></name><name><surname>Stoeckius</surname> <given-names>M</given-names></name><name><surname>Legut</surname> <given-names>M</given-names></name><name><surname>Roush</surname> <given-names>T</given-names></name><name><surname>Herrera</surname> <given-names>A</given-names></name><name><surname>Papalexi</surname> <given-names>E</given-names></name><name><surname>Ouyang</surname> <given-names>Z</given-names></name><name><surname>Satija</surname> <given-names>R</given-names></name><name><surname>Sanjana</surname> <given-names>NE</given-names></name><name><surname>Koralov</surname> <given-names>SB</given-names></name><name><surname>Smibert</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Multiplexed detection of proteins, transcriptomes, clonotypes and CRISPR perturbations in single cells</article-title><source>Nature Methods</source><volume>16</volume><fpage>409</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1038/s41592-019-0392-0</pub-id><pub-id pub-id-type="pmid">31011186</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monaco</surname> <given-names>G</given-names></name><name><surname>Lee</surname> <given-names>B</given-names></name><name><surname>Xu</surname> <given-names>W</given-names></name><name><surname>Mustafah</surname> <given-names>S</given-names></name><name><surname>Hwang</surname> <given-names>YY</given-names></name><name><surname>Carré</surname> <given-names>C</given-names></name><name><surname>Burdin</surname> <given-names>N</given-names></name><name><surname>Visan</surname> <given-names>L</given-names></name><name><surname>Ceccarelli</surname> <given-names>M</given-names></name><name><surname>Poidinger</surname> <given-names>M</given-names></name><name><surname>Zippelius</surname> <given-names>A</given-names></name><name><surname>Pedro de Magalhães</surname> <given-names>J</given-names></name><name><surname>Larbi</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>RNA-Seq signatures normalized by mRNA abundance allow absolute deconvolution of human immune cell types</article-title><source>Cell Reports</source><volume>26</volume><fpage>1627</fpage><lpage>1640</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.01.041</pub-id><pub-id pub-id-type="pmid">30726743</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Mulè</surname> <given-names>MP</given-names></name><name><surname>Martins</surname> <given-names>AJ</given-names></name><name><surname>Tsang</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Normalizing and denoising protein expression data from droplet-based single cell profiling</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.02.24.963603</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Huallachain</surname> <given-names>M</given-names></name><name><surname>Bava</surname> <given-names>FA</given-names></name><name><surname>Shen</surname> <given-names>M</given-names></name><name><surname>Dallett</surname> <given-names>C</given-names></name><name><surname>Paladugu</surname> <given-names>S</given-names></name><name><surname>Samusik</surname> <given-names>N</given-names></name><name><surname>Yu</surname> <given-names>S</given-names></name><name><surname>Hussein</surname> <given-names>R</given-names></name><name><surname>Hillman</surname> <given-names>GR</given-names></name><name><surname>Higgins</surname> <given-names>S</given-names></name><name><surname>Lou</surname> <given-names>M</given-names></name><name><surname>Trejo</surname> <given-names>A</given-names></name><name><surname>Qin</surname> <given-names>L</given-names></name><name><surname>Tai</surname> <given-names>YC</given-names></name><name><surname>Kinoshita</surname> <given-names>SM</given-names></name><name><surname>Jager</surname> <given-names>A</given-names></name><name><surname>Lashkari</surname> <given-names>D</given-names></name><name><surname>Goltsev</surname> <given-names>Y</given-names></name><name><surname>Ozturk</surname> <given-names>S</given-names></name><name><surname>Nolan</surname> <given-names>GP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Ultra-high throughput single-cell analysis of proteins and RNAs by split-pool synthesis</article-title><source>Communications Biology</source><volume>3</volume><elocation-id>213</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-020-0896-2</pub-id><pub-id pub-id-type="pmid">32382044</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Overall</surname> <given-names>SA</given-names></name><name><surname>Toor</surname> <given-names>JS</given-names></name><name><surname>Hao</surname> <given-names>S</given-names></name><name><surname>Yarmarkovich</surname> <given-names>M</given-names></name><name><surname>O'Rourke</surname> <given-names>SM</given-names></name><name><surname>Morozov</surname> <given-names>GI</given-names></name><name><surname>Nguyen</surname> <given-names>S</given-names></name><name><surname>Japp</surname> <given-names>AS</given-names></name><name><surname>Gonzalez</surname> <given-names>N</given-names></name><name><surname>Moschidi</surname> <given-names>D</given-names></name><name><surname>Betts</surname> <given-names>MR</given-names></name><name><surname>Maris</surname> <given-names>JM</given-names></name><name><surname>Smibert</surname> <given-names>P</given-names></name><name><surname>Sgourakis</surname> <given-names>NG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>High throughput pMHC-I tetramer library production using chaperone-mediated peptide exchange</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>1909</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-15710-1</pub-id><pub-id pub-id-type="pmid">32312993</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname> <given-names>VM</given-names></name><name><surname>Zhang</surname> <given-names>KX</given-names></name><name><surname>Kumar</surname> <given-names>N</given-names></name><name><surname>Wong</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Wilson</surname> <given-names>DC</given-names></name><name><surname>Moore</surname> <given-names>R</given-names></name><name><surname>McClanahan</surname> <given-names>TK</given-names></name><name><surname>Sadekova</surname> <given-names>S</given-names></name><name><surname>Klappenbach</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Multiplexed quantification of proteins and transcripts in single cells</article-title><source>Nature Biotechnology</source><volume>35</volume><fpage>936</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1038/nbt.3973</pub-id><pub-id pub-id-type="pmid">28854175</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Setliff</surname> <given-names>I</given-names></name><name><surname>Shiakolas</surname> <given-names>AR</given-names></name><name><surname>Pilewski</surname> <given-names>KA</given-names></name><name><surname>Murji</surname> <given-names>AA</given-names></name><name><surname>Mapengo</surname> <given-names>RE</given-names></name><name><surname>Janowska</surname> <given-names>K</given-names></name><name><surname>Richardson</surname> <given-names>S</given-names></name><name><surname>Oosthuysen</surname> <given-names>C</given-names></name><name><surname>Raju</surname> <given-names>N</given-names></name><name><surname>Ronsard</surname> <given-names>L</given-names></name><name><surname>Kanekiyo</surname> <given-names>M</given-names></name><name><surname>Qin</surname> <given-names>JS</given-names></name><name><surname>Kramer</surname> <given-names>KJ</given-names></name><name><surname>Greenplate</surname> <given-names>AR</given-names></name><name><surname>McDonnell</surname> <given-names>WJ</given-names></name><name><surname>Graham</surname> <given-names>BS</given-names></name><name><surname>Connors</surname> <given-names>M</given-names></name><name><surname>Lingwood</surname> <given-names>D</given-names></name><name><surname>Acharya</surname> <given-names>P</given-names></name><name><surname>Morris</surname> <given-names>L</given-names></name><name><surname>Georgiev</surname> <given-names>IS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>High-Throughput mapping of B cell receptor sequences to antigen specificity</article-title><source>Cell</source><volume>179</volume><fpage>1636</fpage><lpage>1646</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.11.003</pub-id><pub-id pub-id-type="pmid">31787378</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoeckius</surname> <given-names>M</given-names></name><name><surname>Hafemeister</surname> <given-names>C</given-names></name><name><surname>Stephenson</surname> <given-names>W</given-names></name><name><surname>Houck-Loomis</surname> <given-names>B</given-names></name><name><surname>Chattopadhyay</surname> <given-names>PK</given-names></name><name><surname>Swerdlow</surname> <given-names>H</given-names></name><name><surname>Satija</surname> <given-names>R</given-names></name><name><surname>Smibert</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Simultaneous epitope and transcriptome measurement in single cells</article-title><source>Nature Methods</source><volume>14</volume><fpage>865</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4380</pub-id><pub-id pub-id-type="pmid">28759029</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoeckius</surname> <given-names>M</given-names></name><name><surname>Zheng</surname> <given-names>S</given-names></name><name><surname>Houck-Loomis</surname> <given-names>B</given-names></name><name><surname>Hao</surname> <given-names>S</given-names></name><name><surname>Yeung</surname> <given-names>BZ</given-names></name><name><surname>Mauck</surname> <given-names>WM</given-names></name><name><surname>Smibert</surname> <given-names>P</given-names></name><name><surname>Satija</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cell hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics</article-title><source>Genome Biology</source><volume>19</volume><elocation-id>224</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-018-1603-1</pub-id><pub-id pub-id-type="pmid">30567574</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuart</surname> <given-names>T</given-names></name><name><surname>Butler</surname> <given-names>A</given-names></name><name><surname>Hoffman</surname> <given-names>P</given-names></name><name><surname>Hafemeister</surname> <given-names>C</given-names></name><name><surname>Papalexi</surname> <given-names>E</given-names></name><name><surname>Mauck</surname> <given-names>WM</given-names></name><name><surname>Hao</surname> <given-names>Y</given-names></name><name><surname>Stoeckius</surname> <given-names>M</given-names></name><name><surname>Smibert</surname> <given-names>P</given-names></name><name><surname>Satija</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Comprehensive integration of Single-Cell data</article-title><source>Cell</source><volume>177</volume><fpage>1888</fpage><lpage>1902</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.05.031</pub-id><pub-id pub-id-type="pmid">31178118</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Vreden</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Titration of mass cytometry reagents</article-title><source>Methods in Molecular Biology</source><volume>1989</volume><fpage>83</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-9454-0_6</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.61973.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Weigel</surname><given-names>Detlef</given-names></name><role>Reviewing Editor</role><aff><institution>Max Planck Institute for Developmental Biology</institution><country>Germany</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Ordovas-Montanes</surname><given-names>José</given-names> </name><role>Reviewer</role><aff><institution>Boston Children's Hospital</institution><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Duchene</surname><given-names>Johan</given-names> </name><role>Reviewer</role><aff><institution>Ludwig Maximilians University of Munich</institution><country>Germany</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The work teaches us how to optimize oligo-conjugated antibodies for droplet-based scRNA-seq studies (CITE-seq). This study provides a careful assessment of oligo-conjugated antibody signal in CITE-seq, testing several relevant variables, and clearly demonstrating that antibody titration is a crucial step to optimize a CITE-seq panel.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Improving oligo-conjugated antibody signal in multimodal single-cell analysis&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by Michael Eisen as the Senior and Reviewing Editor. The following individuals involved in review of your submission have agreed to reveal their identity: José Ordovas-Montanes (Reviewer #1); Johan Duchene (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is &quot;in revision at <italic>eLife</italic>&quot;. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)</p><p>Summary:</p><p>In the study by Buus et al., the authors set out to address an important need to understand how oligo-conjugated antibodies should be optimally utilized in droplet-based scRNA-seq studies. These techniques, often referred to as CITE-seq, complement techniques such as flow cytometry and mass cytometry yet also further extend them by the ability to jointly measure intra-cellular RNA-based cell states together with antibody-based measurements. As is the case with flow cytometry, manufacturers provide staining recommendations, yet encourage users to titrate antibodies on their specific samples in order to derive a final staining panel. Based on the ability to stain with hundreds of antibodies jointly, few studies to date have assessed how the antibodies present in these pre-made staining panels respond to a standard titration curve. In order to address this point, this study tests two dilution factors, staining volume, cell count, and tissue of origin to understand the relationships between signal and background for a commercially available antibody panel. They arrive at the general recommendation that these panels could be improved, grouping various antibodies into distinct categories.</p><p>This study is of general interest to the scRNA-seq and CITE-seq communities as it draws attention to this important aspect of CITE-seq panel design. However, given the title is &quot;improving oligo-conjugated antibody in multi-modal single cell analysis&quot;, the manuscript would be substantially improved by not only providing suggestions but also testing at least one, if not more, of their suggestions from Supplementary Table 2, and preferably performing experiments using more technical replicates or biological replicates. As it stands now, the study is largely based on one PBMC and one lung sample, that were stained once with each manipulation as far as can be gathered from the Methods.</p><p>Recombinant antibodies are the most common and powerful reagents in life science research to identify and study proteins. Yet, every single antibody should always be validated and carefully tested for its relevant application, to ensure constructive and reproductive scientific endeavor. I was thus extremely pleased to review the manuscript of Terkild Buus et al., as it provides a careful assessment of oligo-conjugated antibody signal in CITE-seq. The authors tested four variables (antibody concentration, staining volume, cell numbers and tissue origin) and clearly showed that antibody titration is a crucial step to optimize CITE-seq panel. The authors found that, as a general rule, concentration in the 0.625 and 2.5 µg/mL range provides the best results while recommended concentrations by vendors, 5 to 10 µg/mL range, increase background signal.</p><p>Essential revisions:</p><p>1. The starting concentration used for each antibody was based on historical experience and assumptions about the abundance of the epitopes. This approach may not be ideal, and the optimal concentration may have been missed. Do the authors think that a proper titration would be an advantage? Maybe this could be discussed in the text.As a means of testing, we suggest a full titration curve of selected antibodies, perhaps one from each of the categories, but if cost is a concern at least two or three antibodies, to identify how titration impacts antibodies, and especially those in categories labeled as in need of improvement. Relatedly, if the idea is that if antibodies (such as gD-TCR) do not have a cognate receptor leading to general background spread, does spiking in a cell that is a known positive in increasing ratios remedy this issue by acting as a target for the antibodies? Does adding extra washes help to remedy these issues of background?</p><p>2. Another way of improving these panels is through reducing the costs spent on both staining but perhaps more importantly the sequencing-based readouts. Several times in the manuscript (at line 77 for example or line 277) it is alluded to that the background signal of antibodies can make up a substantial cost of sequencing these libraries. However, no formal data on cost is presented, which would be important to formalize the author's points. It would be important to provide cost calculations and recommendations on sequencing depth of ADT libraries based on variation of staining concentration. Relatedly, in the methods, sequencing platform and read depth for ADT libraries was not discussed, nor is the RNA-seq quality control metrics provided other than a mention of ~5,000 reads/cell targeted. This is important to report in all transcriptomic studies, and especially a methods development study.</p><p>3. One of the powerful elements of joint multi-modal profiling, as mentioned in the title, is to be able to measure protein and RNA from a single cell. This study does not formally look at correlation of protein and RNA levels, and whether a decrease in concentration of antibody either improves or diminishes this correlation. This would be important to test with in this study to ensure that decreasing antibody levels does not then adversely affect the power of correlating protein with RNA, and whether it may even improve it.</p><p>Relatedly, the authors showed by testing four variables (see above) that they could define the optimal conditions to reduce background signal and increase sensitivity of antibodies and thus this way improves CITE-seq outcome. Nevertheless, the authors rely on the fact that all antibodies used in their panel are specific for their targeted antigens. It is not necessary to experimentally test the specificity of every single antibody used in the study as this would be a colossal amount of work. But I feel that this aspect should be discussed in the manuscript, especially when an &quot;uncommon&quot; antibody is intended to be used in the CITE-seq panel; the specificity of this antibody should be indeed tested prior to its use.</p><p>4. How was the lack of antibody binding determined for Category E? CD56 is frequently detected on NK cells in peripheral blood, CD117 should be detected on mast cells in lung, and CD127 should be found on T cells, particularly CD8<sup>+</sup> T cells. From inspecting Figure 1E, it appears as if all three of these markers are detected on small but consistent cell subsets. As the clusters are only numbered and no supplementary table is provided to help to reader in their interpretation, it is difficult to determine if these represent rare but specific binding, or have not bound with any specificity.</p><p>5. References: At 14 references, the paper overall could benefit from a more comprehensive citation of related literature including flow cytometry and/or CyTOF best practices for antibody staining and dealing with background, and joint RNA and protein measurement from single cells.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.61973.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Summary:</p><p>In the study by Buus et al., the authors set out to address an important need to understand how oligo-conjugated antibodies should be optimally utilized in droplet-based scRNA-seq studies. These techniques, often referred to as CITE-seq, complement techniques such as flow cytometry and mass cytometry yet also further extend them by the ability to jointly measure intra-cellular RNA-based cell states together with antibody-based measurements. As is the case with flow cytometry, manufacturers provide staining recommendations, yet encourage users to titrate antibodies on their specific samples in order to derive a final staining panel. Based on the ability to stain with hundreds of antibodies jointly, few studies to date have assessed how the antibodies present in these pre-made staining panels respond to a standard titration curve. In order to address this point, this study tests two dilution factors, staining volume, cell count, and tissue of origin to understand the relationships between signal and background for a commercially available antibody panel. They arrive at the general recommendation that these panels could be improved, grouping various antibodies into distinct categories.</p></disp-quote><p>We appreciate the reviewers insight into the methodology and enthusiasm for the study. We do want to clarify that the study does not use a “pre-made staining panel” from commercial vendor, but rather a cocktail of individual antibodies available from a commercial vendor (with emphasis on epitopes relevant to immunology and cancer research). We have also clarified this in the text of the manuscript.</p><disp-quote content-type="editor-comment"><p>This study is of general interest to the scRNA-seq and CITE-seq communities as it draws attention to this important aspect of CITE-seq panel design. However, given the title is &quot;improving oligo-conjugated antibody in multi-modal single cell analysis&quot;, the manuscript would be substantially improved by not only providing suggestions but also testing at least one, if not more, of their suggestions from Supplementary Table 2, and preferably performing experiments using more technical replicates or biological replicates. As it stands now, the study is largely based on one PBMC and one lung sample, that were stained once with each manipulation as far as can be gathered from the Methods.</p></disp-quote><p>We hope that the added analysis, our point by point response to the issues raised by the reviewer, and inclusion of new CITE-seq data from the panel with adjusted concentrations to alleviates the main concerns of the reviewers. We appreciate the suggestions and believe that we now present a much-improved manuscript for your review.</p><disp-quote content-type="editor-comment"><p>Recombinant antibodies are the most common and powerful reagents in life science research to identify and study proteins. Yet, every single antibody should always be validated and carefully tested for its relevant application, to ensure constructive and reproductive scientific endeavor. I was thus extremely pleased to review the manuscript of Terkild Buus et al., as it provides a careful assessment of oligo-conjugated antibody signal in CITE-seq. The authors tested four variables (antibody concentration, staining volume, cell numbers and tissue origin) and clearly showed that antibody titration is a crucial step to optimize CITE-seq panel. The authors found that, as a general rule, concentration in the 0.625 and 2.5 µg/mL range provides the best results while recommended concentrations by vendors, 5 to 10 µg/mL range, increase background signal.</p><p>Essential revisions:</p><p>1. The starting concentration used for each antibody was based on historical experience and assumptions about the abundance of the epitopes. This approach may not be ideal, and the optimal concentration may have been missed. Do the authors think that a proper titration would be an advantage? Maybe this could be discussed in the text.As a means of testing, we suggest a full titration curve of selected antibodies, perhaps one from each of the categories, but if cost is a concern at least two or three antibodies, to identify how titration impacts antibodies, and especially those in categories labeled as in need of improvement. Relatedly, if the idea is that if antibodies (such as gD-TCR) do not have a cognate receptor leading to general background spread, does spiking in a cell that is a known positive in increasing ratios remedy this issue by acting as a target for the antibodies? Does adding extra washes help to remedy these issues of background?</p></disp-quote><p>These are excellent points. We agree that using starting concentrations based on historical experience etc. may not be ideal for a completely objective assessment of how oligo-conjugated antibodies respond to the four-variables test. However, we firmly believe that using informed starting concentrations greatly increases the potential improvement of a panel while keeping costs to a minimum (which has to be a consideration for these expensive methods). With that said, we agree that this approach may not reach <italic>the</italic> optimal concentration (a definition that is a bit complex in this setting). Full titration curves have previously been published showing that oligo-conjugated antibodies respond to titration, and in that regard behave similar to fluorophore-conjugated antibodies assayed by flow cytometry (see Stoeckius et al. 2018. Genome Biology; Figure 3A-D). Our study does not aim to identify the optimal concentration of individual antibodies in isolation but strives to provide the optimal signal-to-noise ratio for each antibody in a cocktail while taking sequencing requirements into account – this is why we don’t focus on full titration curves and saturation kinetics for each antibody/epitope. If we use all antibodies at their highest signal-to-noise ratios, this would drastically increase sequencing requirements of the library as highly expressed markers would use the vast majority of the total sequencing reads. As such, we aimed to get “sufficient” signal-to-noise while keeping the sequencing allocated to each marker balanced. We have elaborated on this in the discussion of the revised manuscript.</p><p>Furthermore, as our results show, background signal can be largely attributed to free-floating antibodies in the solution, using high concentrations for all markers in one or more condition would increase the background in all conditions if these were multiplexed into the same droplet segregation. This phenomenon would likely obscure the positive signals and possibly titration response at lower concentrations (similar to what we see for category A antibodies). To avoid this, if full titration curves should be meaningful, each condition should be run in its own droplet segregation making such titration efforts prohibitively costly. We have elaborated on this in the discussion of the revised manuscript.</p><p>We agree that it would greatly improve the study to include results from our panel with adjusted concentrations. In the revised manuscript, we have made efforts to address this by making a comparison between the sample stained with the pre-titration (DF1) concentrations and a sample stained with concentrations that have adjusted based on their assigned categories (from Table 1). We believe that this new data convincingly demonstrates improvements both of the individual antibody signals and at the level of the increased sequencing balance (see new Figure 5). While the adjusted concentrations could still benefit from further improvements, we show that at similar sequencing depths, the adjusted concentrations provide a more balanced sequencing output and exhibit a 57 % increase in the median positive signal and a 43 % reduction in the median background signal for the 52 antibodies in our panel. The benefit of the adjusted concentration was particularly remarkable for CD86 which went from having 76.5 % to 12.6 % of UMIs assigned to background signal and thus yielded comparable positive signal while using 4.8 fold less UMIs (new Figure 5G).</p><p>Spiking in cells that express the cognate antigen is an interesting idea. However, as the spiked in cells would be included in all the downstream processes including sequencing of mRNA and other modalities, it would be quite costly to spike-in cells that are not of biological interest – only to decrease background of one or a few antibodies.</p><p>While the results presented in the manuscript do not address this directly, our data strongly suggest that adding extra washing would help reduce free-floating antibodies in the solution captured in the gel-bead emulsions responsible for some of the observed background signal (as can be assayed by the non-cell-containing droplets). For such a test to make sense, the staining conditions should be identical for two samples that are differentially washed (including the exact same cell composition) and would require fully separate droplet segregations (i.e. utilization of separate 10x lanes) which would make it a very costly experiment solely to test the washing effect. However, we have done preliminary tests using short (150bp) cDNA amplicon spiked into different tubes or plates containing ~750x10<sup>3</sup> PBMCs to determine washing efficiency by qPCR. Here we assayed how increasing the washing volume from 200µl (96-well) to 1.5mL or 50mL for two washes reduced the detection of the spiked-in amplicon in the supernatant as compared to an unwashed sample. While short cDNA amplicons may not behave identical to oligo-conjugated antibodies, they simulate background signal stemming from free-floating antibodies and thus can be used to evaluate different washing conditions for a given set-up. As expected, using higher washing volumes does indeed greatly reduce the amount of amplicon (simulating free-floating “background” antibodies) detected in the resulting suspension.</p><fig id="respfig1"><label>Author response image 1.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-resp-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>2. Another way of improving these panels is through reducing the costs spent on both staining but perhaps more importantly the sequencing-based readouts. Several times in the manuscript (at line 77 for example or line 277) it is alluded to that the background signal of antibodies can make up a substantial cost of sequencing these libraries. However, no formal data on cost is presented, which would be important to formalize the author's points. It would be important to provide cost calculations and recommendations on sequencing depth of ADT libraries based on variation of staining concentration. Relatedly, in the methods, sequencing platform and read depth for ADT libraries was not discussed, nor is the RNA-seq quality control metrics provided other than a mention of ~5,000 reads/cell targeted. This is important to report in all transcriptomic studies, and especially a methods development study.</p></disp-quote><p>Thank you for pointing out the very sparse description of choice of sequencing method and RNA-seq quality controls. We have included additional metrics in the Materials and methods and included a new Figure 1—figure supplement 1 showing number of detected genes as well as UMI counts within the mRNA and ADT modalities in the revised manuscript. We agree that reducing sequencing cost (without reducing biological information) is a major reason for optimizing staining with oligo-conjugated antibodies. We have now added a section in which we elaborate on the potential cost saving, and other benefits of titration of antibody panels and provide some examples from our datasets. Actual savings of optimization of these panels will be very dependent on a given setup, starting concentrations and the depth of sequencing that the particular research questions (and budget) warrant.</p><p>Due to the 10-1000 fold higher numbers of proteins as compared to coding mRNA [16], ADT libraries have high library complexity (unique UMI content) and are rarely sequenced near saturation. Thus, either sequencing deeper or squandering fewer reads on a handful of antibodies, will result in an increased signal from other antibodies in the panel. We found that by simply reducing the concentration of the five antibodies used at 10 µg/mL, we gained 17 % more reads for the remaining antibodies. Consequently, assuming we are satisfied with the magnitude of signal we got from all other antibodies using the starting concentration, this directly translates to a 17 % reduction in sequencing costs.</p><p>In terms of sequencing depth, we are not comfortable giving very broad recommendations. This is due to the fact that sequencing requirements will be very different depending on the composition of the antibody panel as well as the cell type distribution (epitope abundance) (as has been previously noted in Mair et al. 2020 Cell Rep.). If the antibody panel contains only antibodies targeting epitopes that are largely present on a small subset of cells (such as CD56 or CD8 for PBMCs) it would require fewer reads per marker per total cell count than markers that are broadly expressed (such as HLA-ABC or CD45 for PBMCs). However, in a different sample composition (for instance a tissue with few leukocytes) these same antibodies would require fewer reads per cell whereas other epitopes may be more abundant.</p><p>We want to also stress, that aside from cost savings, an optimized balanced panel with low background will yield improved resolution compared to a non-optimized panel. Fortunately, CITE-seq and related methods are very flexible in this regard as you can start by shallow sequencing and then “top-up” the sequencing depth to an optimal level based on the actual data in subsequent sequencing runs (for instance together with the next batch of samples).</p><disp-quote content-type="editor-comment"><p>3. One of the powerful elements of joint multi-modal profiling, as mentioned in the title, is to be able to measure protein and RNA from a single cell. This study does not formally look at correlation of protein and RNA levels, and whether a decrease in concentration of antibody either improves or diminishes this correlation. This would be important to test with in this study to ensure that decreasing antibody levels does not then adversely affect the power of correlating protein with RNA, and whether it may even improve it.</p></disp-quote><p>We appreciate the reviewer’s suggestion – this is a great idea. Unfortunately, such correlations are notoriously hard to do for scRNA-seq data due to the sparsity of the RNA measurements (which contains high frequency of 0 UMI counts). This is, in part, due to low reverse transcriptase efficiency, and also due to the fact that most proteins have 10-1000 fold more copies than the mRNA transcripts that encode them (Marguerat et al. 2012 Cell). This is exacerbated in our study by the fact that we only shallowly sequenced RNA modality (~4000 reads/cell). Consequently, we see a very high number of cells that despite clustering together within distinct lineage clusters (based on their full transcriptome) and expressing the expected lineage marker surface proteins, do not have readily detectable transcript for the same marker(s). For instance, for all cells that are positive for CD8 at the RNA level, there are at least as many that are negative for CD8 RNA while being positive for CD8 ADT. Importantly, these additional CD8<sup>+</sup> cells are still located within clusters consistent with a CD8<sup>+</sup> phenotype (see <xref ref-type="fig" rid="respfig2">Author response image 2</xref>).</p><fig id="respfig2"><label>Author response image 2.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-resp-fig2-v1.tif"/></fig><p>As such, due to the sparsity of RNA counts, if ADT signal is diluted too much leading to truly positive cells being called as negative, it may actually increase individual cell correlation between RNA and ADT but mean higher levels of “false negative” cells. Direct correlation between RNA and antibody measurements within each individual cells is further complicated by the presence of non-specific/background signal in protein data that is rarely found in RNA data. This can also be seen in the <xref ref-type="fig" rid="respfig2">Author response image 2</xref> by the fact that positive cells are defined at a cut-off “7” at the ADT level, and not “0” as is the case for RNA. Thus, while having only a few UMI counts for a given transcript is sufficient to call expression, having a few UMIs from an ADT can easily be attributed to background (particularly in an unoptimized panel).Due to these technical limitations, we find it more suitable to correlate “positivity” called by either ADT (gated positive as shown in Figure 1—figure supplement 2) or mRNA expression (i.e. &gt; 0 UMI counts). While this comparison is less quantitative (does not distinguish “high” from “low” expression) it enables us to show whether reducing antibody concentrations affects ADT signal ability to distinguish positive from negative cells (as compared to GEX), which is at the core of the reviewer’s suggestion. <xref ref-type="fig" rid="respfig3">Author response image 3</xref>, demonstrates that four-fold titration reduces the fraction of positive cells by some markers (reduction in the blue+red bars by dilution) whereas other markers are largely unaffected both of which is consistent with the analysis in the manuscript:</p><fig id="respfig3"><label>Author response image 3.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-61973-resp-fig3-v1.tif"/></fig><p>In terms of assuring specificity, we have also modified the “titration plots” to show more detailed cell type distribution at each rank (by the “barcode plot” to the right of the “rank plot”) as well as the distribution of UMIs among cell types (by the bar plot above the “barcode plot”) at each condition. Finally, to make these “titration plots” more accessible, we have now included a guide to the different components of the “titration plots” in Figure 2 of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Relatedly, the authors showed by testing four variables (see above) that they could define the optimal conditions to reduce background signal and increase sensitivity of antibodies and thus this way improves CITE-seq outcome. Nevertheless, the authors rely on the fact that all antibodies used in their panel are specific for their targeted antigens. It is not necessary to experimentally test the specificity of every single antibody used in the study as this would be a colossal amount of work. But I feel that this aspect should be discussed in the manuscript, especially when an &quot;uncommon&quot; antibody is intended to be used in the CITE-seq panel; the specificity of this antibody should be indeed tested prior to its use.</p></disp-quote><p>Thank you for this suggestion. This is indeed an aspect of antibody optimization that we have not touched upon. By using commercially available oligo-conjugated antibody clones that are broadly used, the extensive testing of many of these clones by multiple labs within immunology community (for flow/mass cytometry applications) and based on our personal experience with majority of the clones for flow cytometry applications, we expected that the antibodies in our panel should be specific for their antigen. This is supported by the labelling matching what we would expect to find in PBMCs and lung leukocytes, as well as the correlation between expression of the gene encoding the targeted epitope and antibody binding (see our response to reviewer 1, point 3). We have added a paragraph to the revised manuscript discussing that, particularly when using antibodies for the first time or using clones that are unfamiliar, it is important to assure specificity.</p><disp-quote content-type="editor-comment"><p>4. How was the lack of antibody binding determined for Category E? CD56 is frequently detected on NK cells in peripheral blood, CD117 should be detected on mast cells in lung, and CD127 should be found on T cells, particularly CD8<sup>+</sup> T cells. From inspecting Figure 1E, it appears as if all three of these markers are detected on small but consistent cell subsets. As the clusters are only numbered and no supplementary table is provided to help to reader in their interpretation, it is difficult to determine if these represent rare but specific binding, or have not bound with any specificity.</p></disp-quote><p>Thank you pointing this out. In light of this comment, it is obvious that we need to annotate the cell types of the clusters. We have annotated all the fine-grained clusters by cell types and re-worked all relevant panels in Figures 1, 2 and 3 (and all their related figure supplements) to show more detailed and consistent cell type annotation. We have also added Figure 1—figure supplement 1C and D to show marker genes for each of the annotated cell types, which together with the re-worked Figure 1E, give the reader a clear description of the cluster identity. We do indeed see some signal for Category E antibodies such as CD56, CD117 and CD127 within the expected clusters. This indicates that the antibodies do work to some extent. However, we also find that the signal for these markers is modest, at best, and not present in some populations where we would have expected them (CD127 should be more pronounced in T cells and we are finding an unexpectedly high frequency of CD56-negative NK cells).</p><disp-quote content-type="editor-comment"><p>5. References: At 14 references, the paper overall could benefit from a more comprehensive citation of related literature including flow cytometry and/or CyTOF best practices for antibody staining and dealing with background, and joint RNA and protein measurement from single cells.</p></disp-quote><p>We agree that the reference list of the original manuscript was sparse and may have missed important relevant studies. We have done our best to include additional studies relevant for the optimization and titration of mass cytometry panels and flow cytometry staining and added references to a few newly published joint RNA and protein measurement studies. We have strived to reference all studies directly relevant to the present work and do not want to overlook any appropriate publications that should be referenced and so welcome any suggestions of the reviewers.</p></body></sub-article></article>